



- (51) **International Patent Classification:**  
*A61K 47/48* (2006.01) *A61K 49/00* (2006.01)
- (21) **International Application Number:**  
PCT/US2013/032200
- (22) **International Filing Date:**  
15 March 2013 (15.03.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/683,305 15 August 2012 (15.08.2012) US
- (71) **Applicant:** VISEN MEDICAL, INC. [US/US]; 940 Winter Street, Waltham, MA 02451 (US).
- (72) **Inventor:** HO, Guojie; 33 Grindstone Lane, Sudbury, MA 01776 (US).
- (74) **Agents:** GUSTAFSON, Megan, A. et al.; Goodwin Procter LLP, Exchange Place, Boston, MA 02109 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report (Art. 21(3))

(54) **Title:** PROSTATE SPECIFIC ANTIGEN AGENTS AND METHODS OF USING SAME FOR PROSTATE CANCER IMAGING

(57) **Abstract:** The invention provides a family of agents that target the prostate specific antigen, which can be used as imaging agents or therapeutic agents. The agents can be used to image prostate cancer as well as other physiological processes in a subject.



WO 2014/028057 A1

- 1 -

## **PROSTATE SPECIFIC ANTIGEN AGENTS AND METHODS OF USING SAME FOR PROSTATE CANCER IMAGING**

### **CROSS REFERENCE TO RELATED APPLICATIONS**

[0001] This application claims the benefit of and priority to United States Provisional Patent Application No. 61/683,305, filed August 15, 2012, the contents of which are hereby incorporated by reference.

### **FIELD OF THE INVENTION**

[0002] The invention provides compositions and methods for detecting prostate cancer  
5 in a subject. The compositions generally contain a prostate specific antigen targeting moiety and an imaging reporter, which may be a fluorophore.

### **BACKGROUND**

[0003] Current approaches for assessing molecular endpoints in certain diseases usually require tissue and blood sampling, surgery, and in the case of experimental animals, sacrifice at different time points. Despite improvements in non-invasive imaging, more sensitive and  
10 specific imaging agents and methods are needed. Imaging techniques capable of visualizing specific molecular targets and/or entire pathways would significantly enhance our ability to diagnose and assess treatment efficacy of therapeutic interventions for many different disease states. Most current imaging techniques report primarily on anatomical or physiological  
15 information (e.g., magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound). Newer modalities such as optical imaging and new molecular imaging probes have the potential to revolutionize the way disease is detected, treated, and monitored.

[0004] A common paradigm for molecular imaging involves the use of a “molecular” probe or agent that selectively targets a particular gene, protein, receptor or a cellular function, with the absence, presence, or level of the specific target being indicative of a particular disease  
20 state. In particular, optical imaging offers several advantages that make it a powerful molecular imaging approach, both in the research and clinical settings. Optical imaging can be fast, safe, cost effective, and highly sensitive. Scan times are on the order of seconds to minutes, there is

- 2 -

no need for ionizing radiation, and the imaging systems can be simple to use. In addition, optical probes can be designed as dynamic molecular imaging agents that may alter their reporting profiles *in vivo* to provide molecular and functional information in real time. In order to achieve maximum penetration and sensitivity *in vivo*, the choice for most optical imaging in biological systems is within the red and near-infrared (NIR) spectral region (600-900 nm), although other wavelengths in the visible region can be used. In the NIR wavelength range, absorption by physiologically abundant absorbers such as hemoglobin or water, as well as tissue autofluorescence, is minimized.

[0005] Prostate cancer is the sixth leading cause of cancer-related death in the world; it is the second leading cause of cancer-related death in the United States. Prostate cancer develops in the prostate, a gland of the male reproductive system. While it can be aggressive, most forms are slow growing cancers. Metastasis, or spreading, of the cancer may occur in other parts of the body such as the bones and lymph nodes. Prostate cancer can cause symptoms such as difficulty during urination, frequent urination, increased nighttime urination, blood in the urine, painful urination, erectile dysfunction, problems during sexual intercourse, and pain.

[0006] Prostate Specific Antigen (PSA) is a protein produced by cells of the prostate gland. PSA was the first identified prostate antigen and has become a premier tumor marker for diagnosis, monitoring, and prognosis of prostatic carcinoma. Prostate specific antigen serves as a molecular target for novel active and passive immunotherapy currently under investigation.

[0007] PSA is not found in significant levels in tissues outside the prostate gland. Under normal conditions, high concentrations of PSA are stored in the prostatic ductal network. Disruption of the normal tissue architecture in the prostate or distal sites by prostate cancer cells causes leakage of increased amounts of PSA into the tissue interstitium and then the circulation.

[0008] Though PSA is used to screen for prostate cancer, a patient's serum PSA level alone does not provide enough information to distinguish benign prostate conditions from actual cancer of the prostate. Furthermore, there are several issues regarding the use of PSA as a target for therapy. First, it is secreted and present in high concentrations in the serum. This can block targeting to tumor cells before a therapeutic or diagnostic agent can bind or enter the

- 3 -

cancer cell. Second, PSA is expressed at lower levels in hormone-resistant cancer.

[0009] One complication to effective prostate cancer screening is the existence of multiple forms of the PSA protein. Within the prostate, peptidases remove amino acid sequences from the immature PSA protein to create the mature, enzymatically active form of the PSA protein. Enzymatically active PSA is only present in prostate tissue. Enzymatically inactive variants of PSA are created when the immature protein is not properly processed. Standard diagnostic tests do not distinguish between enzymatically active and inactive forms of PSA. Small quantities of enzymatically active PSA leak out of the prostatic ductal network into circulation. High serum levels of the enzymatically active form of PSA are only found during prostate cancer. Once in circulation, the active PSA forms complexes with the serum protease inhibitor alpha-1-antichymotrypsin (ACT), while the enzymatically inactive forms remain unbound. The combined totals contribute to the low levels that can be measured in the circulation. High levels of complexed (and therefore enzymatically active) PSA are more likely indicative of the presence of cancer. Targeting the enzymatically active form of PSA would lead to more reliable prostate cancer diagnoses.

[0010] Long term survival from cancer is highly dependent upon early detection and treatment. The ability to detect different patterns of protein expression in healthy versus abnormal prostate tissue can help classify early prostate changes that could lead to cancer. The ability to more accurately and efficiently detect and quantify levels of mature prostate specific antigen will aid in the understanding of pathogenesis and prognosis of prostate cancer, as well as in the determination of the most appropriate treatment regimens.


## SUMMARY OF THE INVENTION

[0011] The invention provides fluorescent imaging agents activated only by the enzymatically active prostate specific antigen, and these agents can be used in a variety of *in vitro* and *in vivo* applications, including but not limited to, screening for prostate cancer. Also provided are agents/ligands that are fluorescent, upon activation, in the far-red or near-infrared region that are of particular utility for *in vivo* imaging of prostate cancer in humans. In addition, agents are provided that, independently, contain a far-red or near-infrared fluorophore that has been modified by a plurality of chemical modifying groups that can be used for optimization of *in vitro* and *in vivo* properties of the agent.

- 4 -

[0012] Accordingly, one aspect of the invention provides a prostate specific antigen activatable agent, wherein the agent comprises (i) a prostate specific antigen targeting moiety comprising an enzymatically cleavable oligopeptide sequence; (ii) two or more imaging reporter moieties chemically linked, optionally through a linker (L) moiety to the prostate specific antigen targeting moiety; and (iii) an optional Pharmacokinetic (PK) modifier chemically linked to the prostate specific antigen targeting moiety. In certain embodiments, the imaging reporter is a fluorescent moiety. In yet other embodiments, imaging reporter bears a plurality of chemical modifying moieties.

[0013] In certain embodiments, the prostate specific antigen activatable agent is represented by Formula (I) or a salt thereof:



wherein F is a fluorophore or a quencher molecule, L is a bond or a linker; and M is a modifier, attached to either C or N terminus, or both, of the oligopeptide.

[0014] In certain embodiments, the agent, upon activation by prostate specific antigen, is fluorescent in the far-red or near-infrared wavelengths.

[0015] In certain embodiments, the PSA-cleavage oligopeptide is a radical of an oligopeptide listed in Table 1.

Table 1. Exemplary Enzymatically Cleavable Oligopeptide Sequences

| Oligopeptide   | SEQ ID NO. |
|--|------------|
| Ac-Lys-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys-NH <sub>2</sub> | 1          |
| Gly-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys-NH <sub>2</sub>    | 2          |
| Gly-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys                    | 3          |
| Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys                        | 4          |
| Ac-Lys-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys                 | 5          |
| Ac-Lys-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys                 | 6          |
| Gly-Ser-Ser-Chg-Gln-Ser-Ser-Lys                        | 7          |
| Gly-Ser-Ser-Phe-Gln-Ser-Ser-Lys                        | 8          |
| Ac-Lys-Ala-Ser-Phe-Gln-Ser-Leu-Lys                     | 9          |
| Hyp-Ser-Chg-Gln-Ser-Lys                                | 10         |
| Ac-Lys-Hyp-Ser-Ser-Phe-Gln-Ser-Ser-Lys                 | 11         |
| Gly-Ala-Ser-Chg-Gln-Ser-Ser-Lys                        | 12         |
| Gly-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys                    | 13         |

- [0016] In certain embodiments, M is selected from the group consisting of a hydrogen, alcohol, sulfonate, polysulfonate, cysteic acid, sulfonamide, sulfoxide, sulfone, carboxylate, ketone, phosphonate, phosphate; iminodiacetate, ethylenediamine tetraacetic acid, diethylenetriamine pentaacetic acid, tetraazacyclododecane tetraacetic acid, an amino acid or polyamino acid, oligo- or polyethylene glycol, amine, quaternary ammonium ion, sugars, glucosamine, galactosamine, mannosamine, polyethylene glycol (PEG) and derivatives thereof, for example, alkoxy polyethylene glycol (for example, methoxypolyethylene glycol, ethoxypolyethylene glycol and the like), branched polypropylene glycol, polypropylene glycol, a graft copolymer of poly-lysine and methoxypolyethyleneglycol, peptides, lipids, fatty acids, palmitate, phospholipids, phospholipid-PEG conjugates, carbohydrates (such as dextran, amino-dextran, carboxymethyl-dextran), polyvinylpyrrolidone, iron oxide nanoparticles, naphthylalanine, phenylalanine, 3,3-diphenylpropylamine, taurine, phosphonates, phosphates, carboxylates and polycarboxylates.


- [0017] In certain embodiments, the bond or linker (L) moiety comprises a divalent radical of a moiety selected from the group consisting of glycine, alanine,  $\beta$ -alanine,  $-\text{NH}-(\text{CH}_2)_n-\text{C}(=\text{O})-$  where  $n = 1-8$ , 4-aminomethylbenzoic acid, cysteic acid, glutamic acid, amino-polyethylene glycol-carboxylic acid, amino-polyethylene glycol amine, ethylenediamine, propylenediamine, spermidine, spermine, hexanediamine, and diamine-amino acids, such as homolysine, lysine, ornithine, diaminobutyric acid and diaminopropionic acid, succinic acid,

- 6 -


glutaric acid, suberic acid, adipic acid, amide, triazole, urea, or thiourea.

**[0018]** In certain embodiments, the chemical modifier(s) M improves the stability, the pharmacokinetics or biodistribution of the agent when administered to a live animal.

**[0019]** In certain embodiments, the compound is one of the following or a salt thereof:




- 7 -





- 8 -



or a compound from Table 4.

[0020] Additional exemplary prostate specific antigen activatable agents include  
5 compounds embraced by Formulae I and II described in the detailed description.

[0021] Another aspect of the invention provides a pharmaceutical composition  
comprising a prostate specific antigen activatable agent and a pharmaceutically acceptable  
excipient.

[0022] Another aspect of the invention provides method of *in vivo* imaging, comprising:  
10 (a) administering to a subject an agent; (b) allowing the agent to distribute within the subject;  
and (c) detecting a signal emitted by the prostate specific antigen activatable agent.

[0023] Another aspect of the invention provides a method of *in vivo* optical imaging, the  
method comprising: (a) administering to a subject an agent, wherein the agent comprises a  
fluorochrome; (b) allowing the agent to distribute within the subject; (c) exposing the subject to  
15 light of a wavelength absorbable by the fluorochrome; and (d) detecting a signal emitted by the  
agent.

[0024] Another aspect of the invention provides a method of *in vivo* imaging, wherein

- 9 -

the signal emitted by the agent is used to construct an image. In other embodiments, the image is a tomographic image. Another aspect of the invention provides a method of *in vivo* optical imaging, wherein steps (a) - (c) described above are repeated at predetermined time intervals thereby to permit evaluation of the emitted signals of the agent (such as a prostate specific antigen imaging agent) in the subject over time. Another aspect of the invention provides a method of *in vivo* optical imaging, wherein steps (a) - (d) described above are repeated at predetermined time intervals thereby to permit evaluation of the emitted signals of the agents (such as prostate specific antigen imaging agents) in the subject over time. Another aspect of the invention provides a method of *in vivo* imaging, wherein the subject is an animal or a human. Another aspect of the invention provides a method of *in vivo* imaging, wherein in step (a) two or more imaging probes whose signal properties are distinguishable from one another are administered to a subject, wherein at least one of the imaging probes is an agent described herein (such as a prostate specific antigen imaging agent).

**[0025]** Another aspect of the invention provides a method of *in vivo* optical imaging, wherein the illuminating and detecting steps are performed using an endoscope, catheter, tomographic system, hand-held optical imaging system, or an intraoperative microscope. In certain embodiments, the method is a method of *in vivo* imaging, wherein the presence, absence, or level of emitted signal is indicative of a disease state. In certain embodiments, the method is a method of *in vivo* imaging, wherein the method is used to detect and/or monitor a disease. In certain embodiments, the disease is selected from the group consisting of dysplasia, neoplasia, and cancer.

**[0026]** Another aspect of the invention provides a method of *in vivo* imaging, wherein, in step (a), cells labeled with an agent described herein (such as a prostate specific antigen imaging agent) are administered to the subject. In other embodiments, the signal emitted by the agent (such as a prostate specific antigen imaging agent) is used to monitor trafficking and localization of the cells.

**[0027]** Another aspect of the invention provides a method of imaging prostate cancer in a subject, the method comprising the steps of: (a) administering an agent to a subject; and (b) detecting the presence of the agent thereby to produce an image representative of prostate cancer.

**[0028]** Another aspect of the invention provides a method of treating a disease in a

- 10 -

subject comprising administering to a subject, either systemically or locally, an agent, wherein the agent comprises a radiolabel that localizes in the disease area and delivers an effective dose of radiation.

5 [0029] Another aspect of the invention provides an *in vitro* imaging method, the method comprising: (a) contacting a sample with an agent; (b) allowing the agent to bind to a biological target; (c) optionally removing unbound agent; and (d) detecting signal emitted from the agent thereby to determine whether the agent has been activated by or bound to the biological target. In certain embodiments, the sample is a biological sample.

10 [0030] Compounds described herein are understood to be efficacious for the binding of prostate specific antigen, as well as for *in vitro* and *in vivo* fluorescence imaging of prostate cancer and therefore can be used for both therapeutic and diagnostic applications.

[0031] In addition, the invention provides methods for *in vitro* and *in vivo* imaging using the fluorescent prostate specific antigen imaging agents. With respect to optical *in vivo* imaging, the method comprises (a) administering to a subject prostate specific antigen  
15 activatable agents of the invention; (b) allowing the prostate specific antigen activatable agents to distribute within the subject; (c) exposing the subject to light of a wavelength absorbable by the fluorophore of the prostate specific antigen activatable agent; and (d) detecting an optical signal emitted by the prostate specific antigen activatable agent. The signal emitted by the agent can be used to construct an image. In certain embodiments, certain of the images are a  
20 tomographic image. Furthermore, it is understood that the foregoing steps can be repeated at predetermined intervals thereby permitting evaluation of the subject over time.

[0032] The prostate specific antigen activatable agents can be formulated into a pharmaceutical composition suitable for administration to a subject, for example, an animal and/or a human subject. The pharmaceutical composition can include one or more of the  
25 prostate specific antigen activatable agents and one or more stabilizers in a physiologically acceptable carrier.

[0033] The subject may be a vertebrate, for example, a mammal, for example, a human. The subject may also be a non-vertebrate (for example, *C. elegans*, *Drosophila*, or another model research organism, etc.) used in laboratory research.

30 [0034] In certain embodiments, the fluorophores can be chosen, for example, from a

- 11 -

series of fluorescent reporters.

[0035] In addition, another aspect of the invention provides methods for *in vitro* and *in vivo* imaging using the prostate specific antigen activatable agents. With respect to optical *in vivo* imaging, one exemplary method comprises (a) administering to a subject one or more of the foregoing prostate specific antigen activatable agents described here, wherein the agents comprise two or more fluorochromes; (b) allowing the agent to distribute within the subject; (c) exposing the subject to light of a wavelength absorbable at least one fluorochrome; and (d) detecting a signal emitted by the prostate specific antigen activatable agent. The signal emitted by the agent can be used to construct an image, for example, a tomographic image.

Furthermore, it is understood that the foregoing steps can be repeated at predetermined intervals, which permit evaluation of the subject over time.

[0036] The prostate specific antigen activatable agents can be used to measure levels of enzymatically active prostate specific antigen (prostate cancer) or other physiological processes such as cancer in a subject. One exemplary method comprises (a) administering one or more of the foregoing prostate specific antigen activatable agents to a subject; (b) detecting the presence of the agent(s) thereby to produce an image representative of sites of prostate specific antigen activity within the subject.

[0037] In each of the foregoing methods, the subject can be a vertebrate, for example, a mammal, for example, a human. The subject also can be a non-vertebrate (for example, *C. elegans*, *drosophila*, or another model research organism, etc.) used in laboratory research.

[0038] In addition, the prostate specific antigen activatable agents can be incorporated into a kit, for example, a kit with optional instructions for using the prostate specific antigen activatable agents in *in vivo* or *in vitro* imaging methods. The kit optionally can include components that aid in the use of the prostate specific antigen activatable agents, for example, buffers, and other formulating agents. Alternatively, the kit can include medical devices that aid in the administration and/or detection of the prostate specific antigen activatable agents to subjects.

[0039] Other features and advantages of the invention will be apparent from the following figures, detailed description, and the claims.

- 12 -

## BRIEF DESCRIPTION OF THE DRAWINGS

[0040] **Figure 1** is a scatter plot comparing the fluorescence of the prostate specific antigen activatable agents when incubated with active PSA versus inactive (complexed) PSA. Data in Figure 1 depict activation of the prostate specific antigen activatable agents (compound A10).

[0041] **Figure 2** depicts tomographic images and total fluorescence for sites of active PSA detected in mice using a prostate specific antigen activatable agents (compound A10). **Figure 2A** depicts epi-fluorescent reflectance and tomographic images of prostate cancer expressing mice six hours post-injection. **Figure 2B** is a histogram comparing fluorescence between prostate cancer expressing (PSA positive) and control (PSA negative) mice injected with the prostate specific antigen activatable agents (compound A10) and imaged tomographically.

## DETAILED DESCRIPTION

[0042] The invention provides compositions and methods for detecting prostate specific antigen in a subject. Technology described herein is based, in part, upon the discovery that it is possible to produce fluorescent prostate specific antigen activatable agents that are stable, biocompatible, exhibit low nonspecific cellular uptake *in vitro*, and low nonspecific tissue uptake *in vivo*, and can be used in a variety of *in vitro* and *in vivo* assays and imaging applications, as well as in a variety of therapeutic applications. Various aspects of the prostate specific antigen activatable agents and their use are described in the section below. Aspects of the invention described in one particular section are not to be limited to any particular section. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls.

### I. PROSTATE SPECIFIC ANTIGEN ACTIVATABLE AGENTS

[0043] One aspect of the invention provides prostate specific antigen activatable agents. The prostate specific antigen activatable agents generally comprise (i) a prostate specific antigen targeting moiety and (ii) an imaging reporter, which may be a fluorophore. The prostate specific antigen targeting moiety may be connected to the imaging reporter (e.g., a fluorophore) via a linker.

[0044] Properties of the prostate specific antigen activatable agent may be adjusted by

- 13 -

selecting particular types of imaging reporter moieties, linker, and prostate specific antigen targeting moieties. In addition, properties of the prostate specific antigen activatable agent can be adjusted by attaching one or more chemical modifying group (M). The prostate specific antigen targeting moiety, linker, fluorophore, and chemical modifying moieties are described in more detail in the sub-sections below.

[0045] The “imaging reporter” or “F” can be any suitable chemical or substance which is used to provide the contrast or signal in imaging and that is detectable by imaging techniques. In certain embodiments, the imaging reporter comprises one or more fluorophores or photoluminescent nanoparticles.

[0046] The term “chemical modifying group” or “M” is understood to mean any moiety that can be used to alter the physical, chemical or biological properties of the prostate specific antigen activatable agent, such as, without limitations, making it more water soluble or more dispersible in media for administration, increasing binding specificity, increasing or decreasing net molecular charge, decreasing immunogenicity or toxicity, or modifying cell uptake, pharmacokinetic or biodistribution profiles compared to the non-M modified prostate specific antigen activatable agents.

[0047] Additional information in prostate specific antigen activatable agents can be found in, for example, U.S. Patent Nos. 7,371,728; 6,127,333; 6,174,858; 6,391,305; 6,177,404; and 6,130,204; and U.S. Patent Application No. 20070244055, all of which are incorporated herein by reference in their entirety.

#### **A. Prostate Specific Antigen Targeting Moiety**

[0048] The prostate specific antigen targeting moiety is generally an enzymatically cleavable oligopeptide sequence. Exemplary prostate specific antigen targeting moieties include a radical the following oligopeptide sequences (also described at least in part in Table 1 above): Gly-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:3); Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:4); Ac-Lys-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:5); Ac-Lys-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:6); Gly-Ser-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:7); and Gly-Ser-Ser-Phe-Gln-Ser-Ser-Lys (SEQ ID NO:8).

#### **B. Imaging Reporters**

- 14 -

[0049] A variety of fluorophores, for example, fluorescent reporters are contemplated to be amenable for use in the present invention. Exemplary fluorophores are described below. The fluorophores may be substituted with a plurality of chemical modifying moieties.

(a) Fluorescent Reporters

5 [0050] In certain embodiments, the imaging reporter is a fluorophore molecule. A “fluorophore” includes, but is not limited to, a fluorochrome, a fluorochrome quencher molecule, any organic or inorganic dye, metal chelate, or any fluorescent enzyme substrate, including protease activatable enzyme substrates.

10 [0051] In certain embodiments, the prostate specific antigen activatable agents comprise a fluorophore. In certain embodiments, the fluorophores are far red and near infrared fluorochromes (NIRFs) with absorption and emission maximum between about 600 and about 1200 nm, more preferably between about 600 nm and about 900 nm. It will be appreciated that the use of fluorochromes with excitation and emission wavelengths in other spectrums can also be employed in the compositions and methods of the present invention. Exemplary  
15 fluorochromes include but are not limited to a carbocyanine fluorochrome and an indocyanine fluorochrome.

[0052] The far red to near infrared fluorochromes preferably have an extinction coefficient of at least 50,000 M<sup>-1</sup>cm<sup>-1</sup> per fluorochrome molecule in aqueous medium. Fluorochromes preferably also have (1) high quantum yield (i.e., quantum yield greater than  
20 5% in aqueous medium), (2) narrow excitation/emission spectrum, spectrally separated absorption and emission spectra (i.e., excitation and emission maxima separated by at least 15 nm), (3) high chemical and photostability, (4) non-toxicity, (5) good biocompatibility, biodegradability and excretability, and (6) commercial viability and scalable production for large quantities (i.e., gram and kilogram quantities) required for *in vivo* and human use.

25 [0053] Certain carbocyanine or polymethine fluorescent dyes can be used to produce the prostate specific antigen activatable agents of the invention and include, for example, those described in U.S. Patent No. 6,747,159; U.S. Patent No. 6,448,008; U.S. Patent No. 6,136,612; U.S. Patent No. 4,981,977; 5,268,486; U.S. Patent No. 5,569,587; U.S. Patent No. 5,569,766; U.S. Patent No. 5,486,616; U.S. Patent No. 5,627,027; U.S. Patent No. 5,808,044; U.S. Patent  
30 No. 5,877,310; U.S. Patent No. 6,002,003; U.S. Patent No. 6,004,536; U.S. Patent No. 6,008,373; U.S. Patent No. 6,043,025; U.S. Patent No. 6,127,134; U.S. Patent No. 6,130,094;

- 15 -

U.S. Patent No. 6,133,445; also WO 97/40104, WO 99/51702, WO 01/21624, and EP 1 065 250 A1; and Tetrahedron Letters 41, 9185-88 (2000).

**[0054]** Various fluorochromes are commercially available and can be used to construct the prostate specific antigen activatable agents of the invention. Exemplary fluorochromes include, for example, Cy5.5, Cy5 and Cy7 (GE Healthcare); AlexaFluor660, AlexaFluor680, AlexaFluor750, and AlexaFluor790 (Invitrogen); VivoTag680, VivoTag-S680, and VivoTag-S750 (PerkinElmer); Dy677, Dy682, Dy752 and Dy780 (Dyomics); DyLight547, DyLight647 (Pierce); HiLyte Fluor 647, HiLyte Fluor 680, and HiLyte Fluor 750 (AnaSpec); IRDye 800CW, IRDye 800RS, and IRDye 700DX (Li-Cor); and ADS780WS, ADS830WS, and ADS832WS (American Dye Source) and Kodak X-SIGHT 650, Kodak X-SIGHT 691, Kodak X-SIGHT 751 (Carestream Health).

**[0055]** Table 2 lists a number of exemplary commercial fluorochromes useful in the practice of the invention together with their spectral properties.


TABLE 2

| Fluorochrome       | $\epsilon_{\max}$ M <sup>-1</sup> cm <sup>-1</sup> | Absorbance max (nm) |
|--------------------|--|---------------------|
| Cy5                | 250,000  | 649                 |
| Cy5.5              | 250,000  | 675                 |
| Cy7                | 250,000  | 743                 |
| AlexaFluor660      | 132,000  | 663                 |
| AlexaFluor680      | 184,000  | 679                 |
| AlexaFluor750      | 280,000  | 749                 |
| VivoTag680 (VT680) | 100,000  | 670                 |
| VivoTag-S680       | 220,000  | 674                 |
| VivoTag-S750       | 100,000  | 750                 |
| Dy677              | 180,000  | 673                 |
| Dy682              | 140,000  | 690                 |
| Dy752              | 270,000  | 748                 |
| Dy780              | 170,000  | 782                 |
| DyLight547         | 150,000  | 557                 |
| DyLight647         | 250,000  | 653                 |
| IRDye800CW         | 240,000  | 774                 |
| IRDye800RS         | 200,000  | 767                 |
| IRDye700DX         | 165,000  | 689                 |
| ADS780WS           | 170,000  | 782                 |
| ADS830WS           | 240,000  | 819                 |
| ADS832WS           | 190,000  | 824                 |



- 16 -

[0056] In certain embodiments, the fluorophore is substituted by a plurality of chemical modifying groups. In certain embodiments, the fluorophore is represented by formula A:



5 or a salt thereof, wherein:

W represents a benzo-condensed, a naphtho-condensed or a pyrido-condensed ring;

X, independently for each occurrence, is selected from the group consisting of

C(CH<sub>2</sub>Y<sub>1</sub>)(CH<sub>2</sub>Y<sub>2</sub>), O, S, and Se;


Y<sub>1</sub> and Y<sub>2</sub> are independently selected from the group consisting of H, C<sub>1</sub>-C<sub>20</sub> aliphatic

10 group, and optionally substituted with L—M;

L, independently for each occurrence, represents a bond or a linker moiety; and

M, independently for each occurrence, represents a modifying moiety.

[0057] In certain other embodiments, the fluorophore is represented by Formula B:



15

or a salt thereof, wherein:

X is independently selected from the group consisting of C(CH<sub>2</sub>Y<sub>1</sub>)(CH<sub>2</sub>Y<sub>2</sub>), O, S, and Se;

Y<sub>1</sub> and Y<sub>2</sub> are independently selected from the group consisting of H, C<sub>1</sub>-C<sub>20</sub> aliphatic group and a C<sub>1</sub>-C<sub>20</sub> aliphatic group substituted with —OR\*, N(R\*)<sub>2</sub> or —SR\*;

20

W represents a benzo-condensed, a naphtho-condensed or a pyrido-condensed ring;

R\* is alkyl;

R<sub>1</sub> is selected from the group consisting of —(CH<sub>2</sub>)<sub>x</sub>CH<sub>3</sub>, —(CH<sub>2</sub>)<sub>n</sub>SO<sub>3</sub><sup>−</sup> and

25

—(CH<sub>2</sub>)<sub>n</sub>SO<sub>3</sub>H, wherein x is an integer selected from 0 to 6 and n is an integer selected from 2 to 6;

- 17 -


$R_4$  is selected from the group consisting of  $-(CH_2)_xCH_3$ ,  $-(CH_2)_nSO_3^-$  and  $-(CH_2)_nSO_3H$ , wherein  $x$  is an integer selected from 0 to 6 and  $n$  is an integer selected from 2 to 6;

$R_2$  and  $R_3$  are independently selected from the group consisting of H, carboxylate, carboxylic acid, carboxylic ester, amine, amide, sulfonamide, hydroxyl, alkoxy, a sulphonic acid moiety and a sulphonate moiety;

$Q$  is -arylene- $C(O)N(R^{**})-(C_{1-8}$  alkylene) $C(O)-$  where the arylene group is covalently bonded to the alkenylene core of Formula B; and

$R^{**}$  is hydrogen or alkyl.

10 [0058] In certain other embodiments, the fluorophore is represented by formula B1:



(B1)

or a salt thereof, wherein:

15  $X$  is independently selected from the group consisting of  $C(CH_2Y_1)(CH_2Y_2)$ , O, S, and Se;

$Y_1$  and  $Y_2$  are independently selected from the group consisting of H,  $C_1$ - $C_{20}$  aliphatic group and a  $C_1$ - $C_{20}$  aliphatic group substituted with  $-OR^*$ ,  $N(R^*)_2$  or  $-SR^*$ ;

$W$  represents a benzo-condensed, a naphtho-condensed or a pyrido-condensed ring;

20  $R^*$  is alkyl;

$R_1$  is selected from the group consisting of  $(CH_2)_xCH_3$ ,  $(CH_2)_nSO_3^-$  and  $(CH_2)_nSO_3H$ , wherein  $x$  is an integer selected from 0 to 6 and  $n$  is an integer selected from 2 to 6;


25  $R_4$  is selected from the group consisting of  $(CH_2)_xCH_3$ ,  $(CH_2)_nSO_3^-$  and  $(CH_2)_nSO_3H$ , wherein  $x$  is an integer selected from 0 to 6 and  $n$  is an integer selected from 2 to 6;

$R_2$  and  $R_3$  are independently selected from the group consisting of H, carboxylate, carboxylic acid, carboxylic ester, amine, amide, sulfonamide, hydroxyl, alkoxy, a sulphonic acid moiety and a sulphonate moiety;

- 18 -


Q is selected from a group consisting of a heteroaryl ring substituted with a carboxyl group or 6-membered heteroaryl ring substituted with a carbonyl group; or Q is selected from a group consisting of (i) a carboxyl functionalized heterocyclic ring, (ii) a carboxyl functionalized nitrogen containing heterocyclic ring, (iii) a carboxyl functionalized nitrogen containing 6-membered heterocyclic ring, such as pyridine, pyrimidine, pyrazine, and pyridazine, (iv) a carboxyl functionalized nitrogen containing 6-membered heterocyclic ring, such as pyridine, and (v) a carbonyl functionalized nitrogen containing 6-membered heterocyclic ring, such as pyridine.

In certain other embodiments, Formula B1 has a variable Q prepared from isonicotinic acid, nicotinic acid and picolinic acid, or a group selected from:



wherein, the carboxyl group is also in the form of an ester, an activated ester or carbonyl halide that is capable of reacting with nucleophiles, and can be, for example, a -C(O)-Obenzotriazolyl, -C(O)-ON-hydroxysuccinimidyl, -C(O)-O-tetrafluorophenyl, -C(O)-O-pentafluorophenyl, -C(O)-O-imidazole, and -C(O)-O-p-nitrophenyl.

**[0059]** In another embodiment, the fluorophore is represented by formula C:



or a salt thereof, wherein:

X is independently selected from the group consisting of C(CH<sub>2</sub>K<sub>1</sub>)(CH<sub>2</sub>K<sub>2</sub>), O, S and Se;

K<sub>1</sub> and K<sub>2</sub> are independently H or C<sub>1</sub>-C<sub>20</sub> aliphatic; or K<sub>1</sub> and K<sub>2</sub> together are part of a substituted or unsubstituted carbocyclic or heterocyclic ring;

Y<sub>1</sub> and Y<sub>2</sub> are each independently a benzo-condensed ring, a naphtha-condensed ring or a pyrido-condensed ring;

- 19 -

$n_1$  is 1, 2, or 3;

$R_2$ ,  $R_{11}$  and  $R_{12}$  are independently H, halogen, alkyl, alkoxy, aryloxy, aryl, a sulfonate, an iminium ion, or any two adjacent  $R_{12}$  and  $R_{11}$  substituents, when taken in combination, form a 4-, 5-, or 6-membered carbocyclic ring optionally substituted one or more times  $C_1$ - $C_6$  alkyl, halogen, or -S-alkyl;

$R_1$  and  $R_{13}$  are  $(CH_2)_xCH_3$ , when  $x$  is an integer selected from 0 to 6; or  $R_1$  and  $R_{13}$  are independently  $(CH_2)_nSO_3^-$  or  $(CH_2)_nSO_3H$  when  $n$  is an integer selected from 2 to 6;

$R_3$ ,  $R_4$  and  $R_5$  are independently selected from the group consisting of H, carboxylate, carboxylic acid, carboxylic ester, amine, amide, sulfonamide, hydroxyl, alkoxyl, a sulphonic acid moiety and a sulphonate moiety;

$R_6$  is unsubstituted  $C_1$ - $C_{20}$  aliphatic, unsubstituted aryl, or unsubstituted alkylaryl;

$R_7$  is H, unsubstituted  $C_1$ - $C_{20}$  aliphatic, unsubstituted aryl, or unsubstituted alkylaryl, wherein  $R_7$  is optionally substituted with halogen; or

$R_6$  and  $R_7$ , taken together form a 4-, 5-, 6- or 7-membered heterocyclic ring optionally substituted with halogen;






W is absent or is a group selected from the group consisting of  $-SO_2NR_6-Q-CHR_7-$ ,  $-O-$ ,  $-C(O)O-$ , and  $-C(O)N(H)-$ ; and

$h = 0-70$ ;  $k = 0$  or 1;  $d = 0-12$ ;  $m = 0-12$ ;  $p = 0-12$ .






**[0060]** Some exemplary chemically modified fluorophores that can be used in the synthesis of the prostate specific antigen activatable agents of the invention include, for example, those listed in Table 3.

- 20 -

TABLE 3.

| No. | Fluorophore  |
|-----|--|
| F1  |    |
| F2  |   |
| F3  |  |
| F4  |  |
| F5  |  |

- 21 -

| No. | Fluorophore  |
|-----|--|
| F6  |    |
| F7  |    |
| F8  |   |
| F9  |  |
| F10 |  |

**[0061]** In certain embodiments, two or more fluorochrome molecules can be chemically linked to the prostate specific antigen targeting moiety to produce the fluorescent prostate specific antigen agents.

**[0062]** In certain embodiments, one of the fluorophores may be replaced by a quencher molecule.

**[0063]** In the case where the imaging reporter is a fluorochrome molecule, the extinction coefficient of the prostate specific antigen activatable agents can be calculated as the ratio of

- 22 -

the absorbance of dye at its absorption maxima (for example at ~670 nm for VivoTag 680) in a 1 cm path length cell to the concentration of particles using the formula  $\varepsilon = A/cl$ , where A is absorbance, c is molar concentration and l is path length in cm.

[0064] Fluorescent silicon nanoparticles may also have the following properties: (1) high quantum yield (i.e., quantum yield greater than 5% in aqueous medium), (2) narrow emission spectrum (i.e., less than 75 nm; more preferably less than 50 nm), (3) spectrally separated absorption and emission spectra (i.e., separated by more than 20 nm; more preferably by more than 50 nm), (3) have high chemical stability and photostability (i.e., retain luminescent properties after exposure to light), (4) are biocompatible (see below) or can be made more biocompatible; (5) are non toxic or minimally toxic to cells or subjects at doses used for imaging protocols, (as measured for example, by LD<sub>50</sub> or irritation studies, or other similar methods known in the art) and/or (6) have commercial viability and scalable production for large quantities (i.e., gram and kilogram quantities) required for *in vivo* and human use.

[0065] Other exemplary fluorophores include metal oxide nanoparticles that are fluorescent and can be used in a variety of *in vitro* and *vivo* applications. In one embodiment, the prostate specific antigen targeting moiety is conjugated to fluorescent metal oxide nanoparticles with one or more of the following features: (1) a polymer coating suitable for attaching a plurality of fluorochromes thereby achieving large extinction coefficients (in excess of 1,000,000 M<sup>-1</sup>cm<sup>-1</sup>), (2) a non-crosslinked polymer coating suitable for attaching from about 10 to about 300 fluorochromes per particle, (3) a polymer coating suitable for attaching a plurality of fluorochromes in a manner that does not significantly compromise the quantum yield of the fluorochromes (e.g., the nanoparticles retain at least 50% of the fluorescent signal that is created by substantially the same number of free fluorochromes when tested under the same conditions), and (4) a polymer coating that is amenable to efficient chemical linking of biomolecules with retention of their biological properties to yield molecular imaging agents. The fluorescent metal oxide nanoparticles are highly stable molecular imaging agents *in vitro*, both before and after chemical linking of fluorochromes and bacterium targeting agents, but yet are labile and/or degradable *in vivo*.

[0066] Furthermore, the prostate specific antigen targeting moiety can be conjugated to molecules capable of eliciting photodynamic therapy. These include, but are not limited to, Photofrin, Lutrin, Antrin, aminolevulinic acid, hypericin, benzoporphyrin derivative, and select

- 23 -

porphyrins.

[0067] In certain embodiments, the imaging agents are incorporated on a nanoparticle with one or more of the following features: (1) a polymer coating suitable for attaching a plurality of agents (2) a non-crosslinked polymer coating suitable for attaching from about 10 to about 300 agents per particle, and (3) a polymer coating that is amenable to efficient chemical linking of the agents with retention of their biological properties to yield molecular imaging agents. The agent modified metal oxide nanoparticle can be a highly stable molecular imaging agent *in vitro*, both before and after chemical linking of the agents, but yet are labile and/or degradable *in vivo*.

10 [0068] It is appreciated that the prostate specific antigen activatable agent conjugated metal oxide nanoparticles can be formulated into a pharmaceutical composition suitable for administration to a subject, for example, an animal and/or a human subject.

**(iii) Ultrasound Reporters**

15 [0069] For ultrasound imaging, the imaging reporter can include gas-filled bubbles such as Levovist, Albunex, or Echovist, or particles or metal chelates where the metal ions have atomic numbers 21-29, 42, 44 or 57-83. Examples of such compounds are described in Tyler et al., *Ultrasonic Imaging*, 3, pp. 323-29 (1981) and D.P. Swanson, "Enhancement Agents for Ultrasound: Fundamentals," *Pharmaceuticals in Medical Imaging*, pp. 682-87 (1990).

**(iv) X-Ray Reporters**

20 [0070] Exemplary reporters can comprise iodinated organic molecules or chelates of heavy metal ions of atomic numbers 57 to 83. Examples of such compounds are described in M. Sovak, ed., "Radiocontrast Agents," Springer-Verlag, pp. 23-125 (1984) and United States patent 4,647,447.

**C. Linkers**

25 [0071] Linker or spacer moieties (L) can be used to chemically link one or more chemical modifiers (M) to the fluorophore and/or to link the prostate specific antigen targeting moiety to Q or, if Q is absent, directly to the fluorophores of the agents of the present invention. Useful linker moieties include both natural and non-natural amino acids and nucleic acids, peptides, such as glycine,  $\beta$ -alanine,  $\gamma$ -aminobutyric acid or aminocaproic acid, as well as  
30 synthetic linker molecules such as aminoethyl maleimide or aminomethyl benzoic acid, or a



- 24 -

polymer such as homobifunctional or heterobifunctional polyethylene glycol (PEG). When the linker is a peptide, the peptide optionally may include proteolytic cleavage site that can be cleaved with a variety of agents, for example, an enzyme.

[0072] It is understood that there is no particular structural, size or content limitation for a given linker. Linkers can include, for example, a variety of functional groups such as maleimide, dithiopyridyl, thiol, azide, alkene, or alkyne that permit the assembly of molecules of diverse architecture.

[0073] Linkers can be homofunctional linkers or heterofunctional linkers. For example, amine (NH<sub>2</sub>)-functionalized moieties can be reacted with bifunctional cross-linkers designed to react with amino groups. Particularly useful conjugation reagents that can facilitate formation of a linker or facilitate covalent linkage between, for example, a fluorophore, and an enzymatically cleavable oligopeptide can include a N-hydroxysuccinimide (NHS) ester and/or a maleimide. The NHS ester can react with the amine group of, for example, a peptide or fluorophore. The maleimide can react with the sulfhydryl group of another molecule. Other particularly useful linker moieties are bifunctional crosslinkers such as N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), long chain-SPDP, maleimidobenzoic acid-N-hydroxysuccinimide ester (MBS), succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate (SMCC), succinimidyl iodoacetate (SIA).

[0074] In certain embodiments a linker, if present, may be a derivative of a diamine. A diamine moiety or derivative can provide a linker arm of varying lengths and chemistries for chemically linking molecules by derivatizing, optionally, with carboxylic acids. Non-limiting examples of diamines include ethylenediamine (EDA), propylenediamine, spermidine, spermine, hexanediamine, and diamine-amino acids, such as homolysine, lysine, ornithine, diaminobutyric acid and diaminopropionic acid. In other embodiments, moieties of an imaging agent can be chemically linked to a dicarboxylic acid, for example, succinic acid, glutaric acid, suberic acid, or adipic acid. In one embodiment, the linker is aminoethylmaleimide.

[0075] In certain embodiments, a linker can be branched, for example glutamic acid or 5-(aminomethyl) isophthalic acid, or a dendrimer, such as a lysine or glutamic acid dendrimer, with multiple M groups linked to a single site on the fluorophore.

[0076] In certain embodiments, L is a functionalized, substituted or unsubstituted C<sub>1</sub>-C<sub>18</sub> alkyl, alkenyl, alkynyl, alkoxy, or thioalkyl group. In other embodiments, L is

- 25 -

functionalized, substituted or unsubstituted aromatic or heteroaromatic ring. In other embodiments, L is absent.

[0077] In certain embodiments, a linker can be formed from an azide moiety that can react with substituted alkynes in an azide-acetylene Huisgen [3+2] cycloaddition. In certain  
5 embodiments the azide or alkyne linker can link a polyethyleneglycol (PEG) moiety to, for example, an enzymatically cleavable oligopeptide. Other contemplated linkers include propargylglycine, pentanoyl, pentynoic acid, propargylic acid, and/or propargylamine moieties.

[0078] In certain embodiments, the imaging reporters are directly chemically linked to the prostate specific antigen targeting moiety using reactive NHS esters groups on the F which  
10 react with the amine group of the amino-functionalized prostate specific antigen targeting moiety. In certain other embodiments, carboxylic acid groups on the F can be activated *in situ* by activating agents known in the art, such as 2-(1H-benzotriazole-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate (HBTU), 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide hydrochloride (EDC), N,N'-dicyclohexylcarbodiimide (DCC), N,N'-  
15 disuccinimidyl carbonate (DSC). In other embodiments, Fs containing a sulfhydryl or thiol group, can be chemically linked to the prostate specific antigen targeting moiety via a bifunctional cross-linker that has a second moiety that can react with a sulfhydryl (thiol) group. Such crosslinking agents include, for example and as described above, SPDP, long chain-SPDP, SIA, MBS, SMCC, and others that are well known in the art.

20 [0079] Useful linker moieties include both natural and non-natural amino acids, oligopeptides, for example, linear or cyclic oligopeptides, and nucleic acids. The linker can be a peptide or peptide moiety. The linker can optionally include a proteolytic or non-proteolytic cleavage site, such as an ester linkage, that can be cleaved due to pH changes at the site of interest.

25 [0080] The term "amino acid" as used herein is understood to mean an organic compound containing both a basic amino group and an acidic carboxyl group. Included within this term are natural amino acids (e.g., L-amino acids), modified and unusual amino acids (e.g., D-amino acids), as well as amino acids which are known to occur biologically in free or combined form but usually do not occur in proteins. Natural amino acids include, but are not  
30 limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine,

- 26 -

tyrosine, tyrosine, tryptophan, proline, and valine. Other amino acids include, but not limited to, arginosuccinic acid, citrulline, cysteine sulfinic acid, 3,4-dihydroxyphenylalanine, homocysteine, homoserine, ornithine, carnitine, selenocysteine, selenomethionine, 3-monoiodotyrosine, 3,5-diiodotryosine, 3,5,5'-triiodothyronine, and 3,3',5,5'-tetraiodothyronine.

5 [0081] Modified or unusual amino acids which can be used to practice the invention include, but are not limited to, D-amino acids, hydroxylysine, dehydroalanine, pyrrolysine, 2-aminoisobutyric acid, gamma aminobutyric acid, 5-hydroxytryptophan, S-adenosyl methionine, S-adenosyl homocysteine, 4-hydroxyproline, an N-Cbz-protected amino acid, 2,4-diaminobutyric acid, homoarginine, norleucine, N-methylaminobutyric acid, naphthylalanine,  
10 phenylglycine, .beta.-phenylproline, tert-leucine, 4-aminocyclohexylalanine, N-methyl-norleucine, 3,4-dehydroproline, N,N-dimethylaminoglycine, N-methylaminoglycine, 4-aminopiperidine-4-carboxylic acid, 6-aminocaproic acid, trans-4-(aminomethyl)-cyclohexanecarboxylic acid, 2-, 3-, and 4-(aminomethyl)-benzoic acid, 1-aminocyclopentanecarboxylic acid, 1-aminocyclopropanecarboxylic acid, and 2-benzyl-5-  
15 aminopentanoic acid.

[0082] As used herein, a "pseudopeptide" or "peptidomimetic" is a compound which mimics the structure of an amino acid residue or a peptide, for example, by using linking groups other than via amide linkages (pseudopeptide bonds) and/or by using non-amino acid substituents and/or a modified amino acid residue. A "pseudopeptide residue" means that  
20 portion of a pseudopeptide or peptidomimetic that is present in a peptide. The term "pseudopeptide bonds" includes peptide bond isosteres which may be used in place of or as substitutes for the normal amide linkage. These substitute or amide "equivalent" linkages are formed from combinations of atoms not normally found in peptides or proteins which mimic the spatial requirements of the amide bond and which should stabilize the molecule to  
25 enzymatic degradation. The following conventional three-letter amino acid abbreviations are used herein: Ala = alanine; Aca = aminocaproic acid, Ahx = 6-aminohexanoic acid, Arg = arginine; Asn = asparagines; Asp = aspartic acid; Cha = cyclohexylalanine; Cit = citrulline; Cys = cysteine; Dap = diaminopropionic acid; Gln = glutamine; Glu = glutamic acid; Gly = glycine; His = histidine; Ile = isoleucine; Leu = leucine; Lys = lysine; Met = methionine; Nal =  
30 naphthylalanine; Nle = norleucine; Orn = ornithine; Phe = phenylalanine; Phg = phenylglycine; Pro = praline; Sar = sarcosine; Ser = serine; Thi = Thienylalanine; Thr = threonine; Trp = tryptophan; Tyr = tyrosine; and Val = valine; Hpy = hydroxylproline; Cha = cyclohexylalanine

- 27 -

; Chg = cyclohexylglycine. Use of the prefix D- indicates the D-isomer of that amino acid; for example D-lysine is represented as D-Lys.

[0083] The peptides can be synthesized using either solution phase chemistry or solid phase chemistry or a combination of both (Albericio, Curr. Opin. Cell Biol., 8, 211-221 (2004), M. Bodansky, Peptide Chemistry: A Practical Textbook, Springer-Verlag; N.L. Benoiton, Chemistry of Peptide Synthesis, 2005, CRC Press).

[0084] Selective or orthogonal amine protecting groups may be required to prepare the agents of the invention. As used herein, the term "amine protecting group" means any group known in the art of organic synthesis for the protection of amine groups. Such amine protecting groups include those listed in Greene, "Protective Groups in Organic Synthesis" John Wiley & Sons, New York (1981) and "The Peptides: Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981). Any amine protecting group known in the art can be used. Examples of amine protecting groups include, but are not limited to, the following: 1) acyl types such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; 2) aromatic carbamate types such as benzyloxycarbonyl (Cbz or Z) and substituted benzyloxycarbonyls, 1-(p-biphenyl)-1-methylethoxycarbonyl, and 9-fluorenylmethyloxycarbonyl (Fmoc); 3) aliphatic carbamate types such as tert-butyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cyclic alkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; 5) alkyl types such as triphenylmethyl and benzyl; 6) trialkylsilane such as trimethylsilane; and 7) thiol containing types such as phenylthiocarbonyl and dithiasuccinoyl. Also included in the term "amine protecting group" are acyl groups such as azidobenzoyl, p-benzoylbenzoyl, o-benzoylbenzoyl, p-acetylbenzoyl, dansyl, glycyl-p-benzoylbenzoyl, phenylbenzoyl, m-benzoylbenzoyl, benzoylbenzoyl.

[0085] In certain embodiments the enzymatically cleavable oligopeptide can include oligo-L-arginine, oligo-L-lysine, oligo-L-aspartic acid or oligo-L-glutamic acid.

[0086] The enzymatically cleavable oligopeptide of the linker is cleavable by at least one enzyme chosen from hydrolases, elastases, cathepsins, matrix metalloproteases, peptidases, exopeptidases, endopeptidases, carboxypeptidases, glycosidases, lipases, nucleases, lyases, amylases, phospholipases, phosphatases, phosphodiesterases, sulfatases, serine proteases, subtilisin, chymotrypsin, trypsin, threonine proteases, cysteine proteases, calpains, papains, caspases, aspartic acid proteases, pepsins, chymosins, glutamic acid proteases, renin,

- 28 -

reductases, and parasitic, viral and bacterial enzymes.

#### **D. Chemical Modifiers**

[0087] Depending upon the intended use, the prostate specific antigen activatable agents can comprise one or more chemical modifiers (M), which can alter the physical, chemical or biological properties of the prostate specific antigen activatable agent. In particular, a plurality of Ms can be chemically linked to the fluorophore moiety of the agent. The Ms can be the same or can be different for each occurrence. For example, the Ms may render the prostate specific antigen activatable agents more useful for biological imaging, that is, for example, more water soluble, or more dispersible in media for administration, with increased binding specificity, or less immunogenic, or less toxic, or with reduced non-specific binding, altered biodistribution and pharmacokinetic compared to an unsubstituted or lesser substituted fluorophore moiety.

[0088] For example, incorporation of methoxypolyethylene glycol (mPEG) or polypeptides or a plurality of anionic Ms may function to modify the pharmacodynamics and blood clearance rates of the prostate specific antigen activatable agents *in vivo*. Other Ms can be chosen to accelerate the clearance of the prostate specific antigen activatable agents from background tissue, such as muscle or liver, and/or from the blood, thereby reducing the background interference and improving image quality. Additionally, the Ms can be used to favor a particular route of excretion, e.g., via the kidneys rather than via the liver. The Ms can also aid in formulating probes in pharmaceutical compositions or may be used to alter or preserve the signal reporting properties of the prostate specific antigen activatable agents. In particular, chemical linking of polyethylene glycol (PEG) or a derivative thereof to prostate specific antigen activatable agents can result in longer blood residence time (longer circulation) and decreasing immunogenicity.

[0089] Exemplary modifiers include polyethylene glycol (PEG) and derivatives thereof (for example, alkoxy polyethylene glycol (for example, methoxypolyethylene glycol, ethoxypolyethylene glycol and the like), branched polypropylene glycol, polypropylene glycol, a graft copolymer of poly-lysine and methoxypolyethyleneglycol, amino acids, peptides, lipids, fatty acids, palmitate, phospholipids, phospholipid-PEG conjugates, carbohydrates (such as dextran, amino-dextran, carboxymethyl-dextran), iron oxide nanoparticles, sulfonates, polysulfonates, cysteic acid, naphthylalanine, phenylalanine, and 3,3-diphenylpropylamine

- 29 -

taurine, phosphonates, phosphates, carboxylates and polycarboxylates.

[0090] In certain embodiments, the chemical modifier M is an anionic moiety selected from the group consisting of carboxylate, phosphonate, phosphate, iminodiacetate, cysteic acid, or taurine.

5 [0091] In certain embodiments, the chemical modifier M is a sulfonate or polysulfonate.

[0092] In certain embodiments, the chemical modifier M is a hydrogen, alcohol, sulfonamide, sulfoxide, sulfone, , ketone, an amino acid such as glutamic acid or taurine, a polyamino acid such as polycysteic acid, oligo- or polyethylene glycol, an amine, a quaternary ammonium ion, or a carbohydrate such as glucosamine, galactosamine or mannosamine.

10 [0093] In certain embodiments, the chemical modifier M is a metal chelator, such as ethylenediamine tetraacetic acid (EDTA), diethylenetriamine pentaacetic acid (DTPA), or tetraazacyclododecane tetraacetic acid (DOTA). In another aspect of the invention, one or more metal chelating M groups are coordinated to a metal ion.

[0094] In certain embodiments, as discussed above, the biological modifier may be a  
15 PEG moiety that has a molecular weight, for example, from about 0.1 kDa to about 50 kDa, about 5 kDa to about 45 kDa, or about 10 kDa to about 40 kDa. Alternatively, the PEG may be dPEG, functionalized at a discrete molecular weight, for example, of about 1100 daltons.

[0095] In certain embodiments, the PEG is methoxyPEG<sub>(5000)</sub>-succinimidylpropionate (mPEG-SPA), methoxyPEG<sub>(5000)</sub>-succinimidylsuccinate (mPEG-SS). Such PEGs are  
20 commercially available from Nektar Therapeutics or SunBiowest or LaysanBio or NOF.

[0096] The PEG moiety can be conjugated to reactive amines on the prostate specific antigen activatable agent via a carboxyl functionality. Alternatively, the PEG modifier can be conjugated to the prostate specific antigen activatable agent by using a thiol reactive cross linker and then reacting with a thiol group on the PEG. Alternatively, the PEG moiety can be  
25 conjugated to reactive carboxylic acid on the prostate specific antigen activatable agent via an amide functionality.

[0097] In one embodiment, the PEG may be branched, or Y-shaped, as available from JenKem USA or NOF, or comb-shaped, or synthesized by coupling two or more PEGs to a small molecule such as glutamic acid.

- 30 -

[0098] In other embodiments, the biological modifier can be polyvinylpyrrolidone (PVP)-type polymers. The biological modifier can be a functionalized polyvinylpyrrolidone, for example, carboxy or amine functionalized on one (or both) ends of the polymer (as available from Polymersource) or within the polymer chain.

5 [0099] Alternatively, the biological modifier can include Poly N-(2-hydroxypropyl)methacrylamide (HPMA), or functionalized HPMA (amine, carboxy, etc.), Poly(N-isopropyl acrylamide) or functionalized poly(N-isopropylacrylamide).

[00100] Biological modifiers can include straight or branched chain acyl groups, such as pentynoyl; acidic groups, such as succinyl; lower alkyl groups, such as methyl, ethyl, propyl,  
10 etc.; carboxyalkyl groups, such as carboxyethyl; haloalkyl groups, such as trifluoromethyl; and the like.

[00101] In general, the chemical linking of Ms does not adversely affect the affinity and/or binding properties of the prostate specific antigen activatable agents.

#### **E. First Group of Exemplary Prostate Specific Antigen activatable agents**

15 [00102] The prostate specific antigen targeting moieties, imaging reporters, linkers, and optionally chemical modifying moieties described above can be combined in different permutations to provide a variety of prostate specific antigen activatable agents.

[00103] Accordingly, one aspect of the invention provides a prostate specific antigen activatable agent that comprises one prostate specific antigen targeting moiety chemically  
20 linked to two fluorophores, wherein a plurality of chemical modifying moieties (M) is chemically linked to the fluorophore. Optionally, one or more linker (L) moieties can be used to chemically link the prostate specific antigen targeting moiety to the fluorophore or the M to the fluorophore.

[00104] In certain embodiments, the prostate specific antigen activatable agent will have  
25 an affinity for enzymatically active prostate specific antigen. In other embodiments, the affinity for enzymatically active prostate specific antigen is greater than enzymatically inactive prostate specific antigen. A “prostate specific antigen targeting moiety”, as defined herein, is a molecule that specifically binds with the mature prostate specific antigen that is enzymatically active.

30 [00105] The “fluorophore” may be any suitable chemical or substance which is used to

- 31 -

provide fluorescent signal or contrast in imaging and that is detectable by imaging techniques. In certain embodiments, fluorophore comprises, for example, a cyanine dye, carbocyanine dye, indocyanine dye, or a polymethine fluorescent dye. In certain embodiments, fluorophore comprises a symmetrical cyanine dye. In other embodiments, fluorophore comprises and  
5 unsymmetrical cyanine dye. In other embodiments, fluorophore may also be modified with a plurality of chemical modifying groups allowing optimization of the *in vitro* and *in vivo* properties of the agent and ultimately the performance of the agent as a fluorescence imaging agent.

[00106] The prostate specific antigen activatable agent can have an affinity for  
10 enzymatically active prostate specific antigen. In certain embodiments, the prostate specific antigen activatable agent binds to the mature enzymatically active prostate specific antigen that is elevated in serum during the pathology of prostate cancer.

[00107] Another aspect of the invention provides prostate specific antigen activatable agent comprising:

15 (i) a prostate specific antigen targeting moiety comprising an enzymatically cleavable oligopeptide sequence; and

(ii) two or more imaging reporters chemically linked, optionally through a linker (L) moiety, to the prostate specific antigen targeting moiety; and

(iii) one or two optional chemical modifying moiety M chemically linked to the prostate  
20 specific antigen targeting moiety.

[00108] The term “chemically linked” is understood to mean connected by an attractive force between atoms strong enough to allow the combined aggregate to function as a unit. This includes, but is not limited to, chemical bonds such as covalent bonds, non-covalent bonds such as ionic bonds, metallic bonds, and bridge bonds, hydrophobic interactions, hydrogen bonds,  
25 and van der Waals interactions.

[00109] Another aspect of the invention provides a prostate specific antigen agent comprising:

(i) a prostate specific antigen targeting moiety comprising an enzymatically cleavable oligopeptide sequence;




- 32 -

(ii) an imaging reporter chemically linked, optionally through a linker (L) moiety, to the prostate specific antigen targeting moiety; and

(iii) a fluorescent reporter chemically linked, optionally through a linker (L) moiety, to the prostate specific targeting activatable moiety wherein the fluorescent moiety bears a plurality of chemical modifying groups.

#### F. Second Group of Exemplary Prostate Specific Antigen Activatable Agents

[00110] Another aspect of the invention provides a compound of formula (I):



or a salt thereof, wherein:

F represents independently for each occurrence a fluorochrome or a quencher;

L represents independently for each occurrence a bond or a linker; and

M is a modifier, attached to either the C or N terminus, or both, of the oligopeptide; and

n represents independently 0 or 1, providing that there is at least one occurrence of M.

[00111] In certain embodiments, the agent is fluorescent in the far-red or near-infrared wavelengths.

[00112] In certain embodiments, the chemical modifying moiety (M) is selected from the group consisting of a hydrogen, alcohol, sulfonate, polysulfonate, cysteic acid, sulfonamide, sulfoxide, sulfone, carboxylate, ketone, phosphonate, phosphate; iminodiacetate, ethylenediamine tetraacetic acid, diethylenetriamine pentaacetic acid, tetraazacyclododecane tetraacetic acid, an amino acid or polyamino acid, oligo- or polyethylene glycol, amine, quaternary ammonium ion, sugars, glucosamine, galactosamine, mannosamine, polyethylene glycol (PEG) and derivatives thereof, for example, alkoxy polyethylene glycol (for example, methoxypolyethylene glycol, ethoxypolyethylene glycol and the like), branched polypropylene glycol, polypropylene glycol, a graft copolymer of poly-lysine and methoxypolyethyleneglycol, peptides, lipids, fatty acids, palmitate, phospholipids, phospholipid-PEG conjugates, carbohydrates (such as dextran, amino-dextran, carboxymethyl-dextran), iron oxide nanoparticles,

- 33 -

naphthylalanine, phenylalanine, 3,3-diphenylpropylamine, taurine, phosphonates, phosphates, carboxylates and polycarboxylates.


[00113] In certain embodiments, the chemical modifying moiety (M) is hydrogen, sulfonate, polysulfonate, sulfonamide, sulfoxide, sulfone, carboxylate, ketone, phosphonate, phosphate, iminodiacetate, or a radical of: an alcohol, cysteic acid, an amine, ethylenediamine tetraacetic acid, diethylenetriamine pentaacetic acid, tetraazacyclododecane tetraacetic acid, an amino acid or polyamino acid, oligo- or polyethylene glycol, quaternary ammonium ion, a sugar, glucosamine, galactosamine, mannosamine, polyethylene glycol (PEG) and derivatives thereof, branched polypropylene glycol, polypropylene glycol, a graft copolymer of poly-lysine and methoxypolyethyleneglycol, a peptide, a lipid, a fatty acid, palmitate, a phospholipid, a phospholipid-PEG conjugate, a carbohydrate, polyvinylpyrrolidone, an iron oxide nanoparticle, naphthylalanine, phenylalanine, 3,3-diphenylpropylamine, taurine, a phosphonate, a phosphate, a carboxylate, or a polycarboxylate.

[00114] In other embodiments, the chemical modifier(s) M reduce the nonspecific cell membrane permeability of the agent. In other embodiments, the chemical modifier(s) M reduce the nonspecific tissue accumulation of the agent when administered to a live animal.

[00115] In certain embodiments, the bond or linker moiety (L) comprises a diradical of a moiety selected from the group consisting of glycine, alanine,  $\beta$ -alanine,  $-\text{NH}-(\text{CH}_2)_n-\text{C}(=\text{O})-$  where  $n = 1-8$ , 4-aminomethylbenzoic acid, cysteic acid, glutamic acid, amino-polyethylene glycol-carboxylic acid, amino-polyethylene glycol amine, ethylenediamine, propylenediamine, spermidine, spermine, hexanediamine, and diamine-amino acids, such as homolysine, lysine, ornithine, diaminobutyric acid and diaminopropionic acid, succinic acid, glutaric acid, suberic acid, adipic acid, amide, triazole, urea, or thiourea.

### G. Third Group of Exemplary Prostate Specific Antigen Activatable Agents

[00116] Another aspect of the invention provides a prostate specific antigen (PSA) activatable agent represented by Formula II:



- 34 -


(II)

or a salt thereof, wherein:

$R^1$  is hydrogen,  $-(C_{1-6} \text{ alkylene})$ -methoxypolyethylene glycol, or  $-(C_{1-6} \text{ alkylene})$ -  
 $N(R^*)C(O)-(C_{1-6} \text{ alkylene})-N(-(C_{1-6} \text{ alkylene})\text{-methoxypolyethylene glycol})C(O)-(C_{1-6}$   
 5  $\text{alkylene})\text{-methoxypolyethylene glycol}$ ;

$R^*$  is hydrogen or unsubstituted  $C_{1-6}$  alkyl;

F represents independently for each occurrence structural Formula IIa or IIb:



(IIa)

wherein:

$R^2$  represents independently for each occurrence hydrogen or unsubstituted  $C_{1-6}$  alkyl, or  
 two adjacent occurrences of  $R^2$  are taken together with the atoms to which they are  
 attached to form a 5- or 6-membered carbocyclic ring;

$R^3$  is hydrogen or unsubstituted  $C_{1-6}$  alkyl, or  $R^3$  and an adjacent occurrence of  $R^2$  are  
 15 taken together with the atoms to which they are attached to form a 5- or 6-membered  
 carbocyclic ring;

$R^4$  is hydrogen or unsubstituted  $C_{1-6}$  alkyl;

$R^5$  represents independently for each occurrence unsubstituted  $C_{1-6}$  alkyl, unsubstituted  
 $C_{1-6}$  alkyl- $SO_3^- M^+$ , or unsubstituted  $C_{1-6}$  alkyl- $SO_3H$ ;

$R^6$  and  $R^7$  each represent independently for each occurrence occurrence hydrogen,  
 20  $-SO_3H$ , or  $-SO_3^- M^+$ ;

M is a monovalent cation or absent;

n is 1, 2, or 3;


W represents a benzo-condensed, a naphtho-condensed, or a pyrido-condensed ring;

25 X represents independently for each occurrence  $C(CH_2Y_1)(CH_2Y_2)$ , O, or S; and

- 35 -

$Y_1$  and  $Y_2$  are independently hydrogen or unsubstituted  $C_{1-6}$  alkyl; and

Formula IIb is represented by:



(IIb)

5 wherein:

$R^{1b}$  and  $R^{3b}$  each represent independently unsubstituted  $C_{1-6}$  alkyl, unsubstituted  $C_{1-6}$  alkyl- $SO_3^- M^+$ , or unsubstituted  $C_{1-6}$  alkyl- $SO_3H$ ;

$R^{2b}$  each represents independently for each occurrence methyl, ethyl, or propyl;

10  $R^{4b}$  and  $R^{5b}$  each represent independently for each occurrence occurrence hydrogen, - $SO_3H$ , or - $SO_3^- M^+$ ;

$R^{6b}$  is hydrogen or  $C_{1-6}$  unsubstituted alkyl;


M is a monovalent cation or absent;

W represents a benzo-condensed, a naphtho-condensed, or a pyrido-condensed ring;

Z is arylene;








15  $X^1$  is unsubstituted  $C_{1-8}$  alkylene; and

the PSA-cleavable oligopeptide is one of the following:




(SEQ ID NO:14)


- 36 -




- 37 -




(SEQ ID NO:22)




(SEQ ID NO:23)




(SEQ ID NO:24)




(SEQ ID NO:25)



(SEQ ID NO:26)








(SEQ ID NO:27)





(SEQ ID NO:28)

- 38 -



5




[00117] In certain embodiments, F is represented by structural Formula IIa. In certain

- 39 -

embodiments, W represents a benzo-condensed ring. In certain embodiments,  $R^6$  and  $R^7$  each represent independently for each occurrence occurrence hydrogen or  $-SO_3H$ .

**[00118]** In certain embodiments, F is represented by the following structural formula:



5 wherein:

$R^2$  represents independently for each occurrence hydrogen or unsubstituted  $C_{1-6}$  alkyl, or two adjacent occurrences of  $R^2$  are taken together with the atoms to which they are attached to form a 5- or 6-membered carbocyclic ring;

10  $R^3$  is hydrogen or unsubstituted  $C_{1-6}$  alkyl, or  $R^3$  and an adjacent occurrence of  $R^2$  are taken together with the atoms to which they are attached to form a 5- or 6-membered carbocyclic ring;

$R^4$  is hydrogen or unsubstituted  $C_{1-6}$  alkyl;


$R^5$  represents independently for each occurrence unsubstituted  $C_{1-6}$  alkyl- $SO_3^- M^+$  or unsubstituted  $C_{1-6}$  alkyl- $SO_3H$ ;

15 M is a monovalent cation or absent;

n is 1, 2, or 3; and


X is  $C(CH_3)_2$  or  $C(CH_2CH_3)_2$ .

20 **[00119]** In certain embodiments,  $R^2$  and  $R^3$  are hydrogen. In certain embodiments,  $R^4$  is methyl. In certain embodiments, n is 2 or 3. In certain embodiments, X is  $C(CH_3)_2$ . In certain embodiments, F is represented by one of the following structural formulae:





- 40 -




5

**[00120]** In certain other embodiments, F is represented by structural Formula IIb. In certain embodiments, W represents a benzo-condensed ring. In certain embodiments  $\text{R}^{4b}$  and  $\text{R}^{5b}$  each represent independently for each occurrence occurrence hydrogen or  $-\text{SO}_3\text{H}$ .

**[00121]** In certain embodiments, F is represented by the following structural Formula:

- 41 -



wherein:

$R^{1b}$  and  $R^{3b}$  each represent independently unsubstituted  $C_{1-6}$  alkyl, unsubstituted  $C_{1-6}$  alkyl-SO<sub>3</sub><sup>-</sup> M<sup>+</sup>, or unsubstituted  $C_{1-6}$  alkyl-SO<sub>3</sub>H;

5  $R^{2b}$  represents independently for each occurrence methyl or ethyl;


$R^{6b}$  is hydrogen or methyl;


M is a monovalent cation or absent;

Z is arylene; and

$X^1$  is unsubstituted  $C_{1-6}$  alkylene.


- 10 **[00122]** In certain embodiments,  $R^{1b}$  and  $R^{3b}$  each represent independently unsubstituted  $C_{1-6}$  alkyl-SO<sub>3</sub><sup>-</sup> M<sup>+</sup> or unsubstituted  $C_{1-6}$  alkyl-SO<sub>3</sub>H. In certain embodiments,  $R^{2b}$  is methyl. In certain embodiments,  $R^{6b}$  is hydrogen. In certain embodiments, Z is a 6-membered




heteroaromatic diradical. In certain embodiments, Z is . In certain embodiments,  $X^1$  is -(CH<sub>2</sub>)<sub>4</sub>-, -(CH<sub>2</sub>)<sub>5</sub>-, or -(CH<sub>2</sub>)<sub>6</sub>-. In certain embodiments, F is represented by one of the

- 15 following structural formulae:


- 42 -



[00123] In certain embodiments, the PSA-cleavable oligopeptide is one of the following:





(SEQ ID NO:14)




(SEQ ID NO:15)

- 43 -




**[00124]** In certain embodiments,  $R^1$  is  $-(C_{1-6} \text{ alkylene})-N(R^*)C(O)-(C_{1-6} \text{ alkylene})-N(-(C_{1-6} \text{ alkylene})\text{-methoxypolyethylene glycol})C(O)-(C_{1-6} \text{ alkylene})\text{-methoxypolyethylene glycol}$ . In

5 certain embodiments,  $R^1$  is . In certain embodiments, the methoxypolyethylene glycol has a weight average molecular weight of about 5,000 g/mol to about 30,000 g/mol. In certain embodiments, the methoxypolyethylene glycol has a weight average molecular weight of about 20,000 g/mol.

**[00125]** In certain other embodiments,  $R^1$  is hydrogen.

**[00126]** Another aspect of the invention provides a prostate specific antigen (PSA) activatable agent represented by Formula III:



(III)

or a salt thereof, wherein:

$p$  is 1, 2, 3, 4, or 5;

$t$  is 1, 2, 3, or 4;

the PSA-cleavable oligopeptide is a mono- or multi-valent radical of an oligopeptide selected from the following:

- 44 -

Ac-Lys-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys-NH<sub>2</sub> (SEQ ID NO:1),Gly-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys-NH<sub>2</sub> (SEQ ID NO:2),

Gly-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:3),

Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:4),

5 Ac-Lys-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:5),

Ac-Lys-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:6),

Gly-Ser-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:7),

Gly-Ser-Ser-Phe-Gln-Ser-Ser-Lys (SEQ ID NO:8),

Ac-Lys-Ala-Ser-Phe-Gln-Ser-Leu-Lys (SEQ ID NO:9),

10 Hyp-Ser-Chg-Gln-Ser-Lys (SEQ ID NO:10),

Ac-Lys-Hyp-Ser-Ser-Phe-Gln-Ser-Ser-Lys (SEQ ID NO:11),


Gly-Ala-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:12), and

Gly-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:13);

15 R<sup>1</sup> is hydrogen, -(C<sub>1-6</sub> alkylene)-methoxypolyethylene glycol, or -(C<sub>1-6</sub> alkylene)-N(R\*)C(O)-(C<sub>1-6</sub> alkylene)-N(-(C<sub>1-6</sub> alkylene)-methoxypolyethylene glycol)C(O)-(C<sub>1-6</sub> alkylene)-methoxypolyethylene glycol;

R\* is hydrogen or unsubstituted C<sub>1-6</sub> alkyl;

F represents independently for each occurrence structural Formula IIIa or IIIb:



(IIIa)

20

wherein:

R<sup>2</sup> represents independently for each occurrence hydrogen or unsubstituted C<sub>1-6</sub> alkyl, or two adjacent occurrences of R<sup>2</sup> are taken together with the atoms to which they are attached to form a 5- or 6-membered carbocyclic ring;

- 45 -

$R^3$  represents independently for each occurrence hydrogen or unsubstituted  $C_{1-6}$  alkyl, or  $R^3$  and an adjacent occurrence of  $R^2$  are taken together with the atoms to which they are attached to form a 5- or 6-membered carbocyclic ring;

$R^4$  is hydrogen or unsubstituted  $C_{1-6}$  alkyl;

5  $R^5$  represents independently for each occurrence unsubstituted  $C_{1-6}$  alkyl, unsubstituted  $C_{1-6}$  alkyl- $SO_3^- M^+$ , or unsubstituted  $C_{1-6}$  alkyl- $SO_3H$ ;

$R^6$  and  $R^7$  each represent independently for each occurrence occurrence hydrogen,  $-SO_3H$ , or  $-SO_3^- M^+$ ;

M is a monovalent cation or absent;


10 n is 1, 2, or 3;

W represents a benzo-condensed, a naphtho-condensed, or a pyrido-condensed ring;

X represents independently for each occurrence  $C(CH_2Y_1)(CH_2Y_2)$ , O, or S; and

$Y_1$  and  $Y_2$  are independently hydrogen or unsubstituted  $C_{1-6}$  alkyl; and

Formula IIIb is represented by:



15

(IIIb)

wherein:

$R^{1b}$  and  $R^{3b}$  each represent independently unsubstituted  $C_{1-6}$  alkyl, unsubstituted  $C_{1-6}$  alkyl- $SO_3^- M^+$ , or unsubstituted  $C_{1-6}$  alkyl- $SO_3H$ ;

20  $R^{2b}$  each represents independently for each occurrence methyl, ethyl, or propyl;

$R^{4b}$  and  $R^{5b}$  each represent independently for each occurrence occurrence hydrogen,  $-SO_3H$ , or  $-SO_3^- M^+$ ;

$R^{6b}$  is hydrogen or  $C_{1-6}$  unsubstituted alkyl;

- 46 -

M is a monovalent cation or absent;

W represents a benzo-condensed, a naphtho-condensed, or a pyrido-condensed ring;

Z is arylene; and

X<sup>1</sup> is unsubstituted C<sub>1-8</sub> alkylene.

- 5    **[00127]**       The description above for Formulae II and III describe multiple embodiments. All combinations of the embodiments are expressly contemplated. Further, because the definitions of the variables in Formulae II above encompass multiple chemical groups, the application contemplates embodiments where, for example, (i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, (ii) the definition is
- 10   a collection of two or more of the chemical groups selected from those set forth above, and (iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).

#### H. Exemplary Prostate Specific Antigen Activatable Agents





- 15   **[00128]**       Useful prostate specific antigen activatable agents can be created using one or more of the prostate specific antigen targeting moieties, imaging reporters, biological modifiers, and linkers described hereinabove using standard chemistries known in the art. Depending upon the particular application, the prostate specific antigen activatable agents can be designed to be water soluble or water dispersible (i.e., sufficiently soluble or suspendable in
- 20   aqueous or physiological media solutions). The prostate specific antigen activatable agents preferably do not have any undesired phototoxic properties and/or display low serum protein binding affinity. Exemplary specified prostate specific antigen activatable agents are listed in Table 4. In certain embodiments, the prostate specific antigen activatable agent is a prostate specific antigen activatable agent listed in Table 4 or a salt thereof.

25

TABLE 4.\*

| Compound No. | Chemical Structure  |
|--------------|---|
| A1           | Ac-Lys(F2*)-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys(F2*)-NH <sub>2</sub> (SEQ ID NO:36) |
| A2           | F4*-Gly-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys(F4*)-NH <sub>2</sub> (SEQ ID NO:37)     |
| A3           | F2*-Gly-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys(F2*)-NH-(mPEG 20,000) (SEQ ID NO:38)    |

- 47 -

| Compound No. | Chemical Structure  |
|--------------|---|
| A4           | Ac-lys(F4*)-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys(F4*)-NH-(mPEG 20,000) (SEQ ID NO:39)  |
| A5           | F8*-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys(F8*)-NH-(mPEG 10,000) (SEQ ID NO:40)  |
| A6           | Ac-lys(F8*)-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys(F8*)-NH-(mPEG 10,000) (SEQ ID NO:41)  |
| A7           | Ac-lys(F4*)-Hyp-Ser-Ser-Phe-Gln-Ser-Ser-Lys(F4*)-NH-(mPEG 20,000) (SEQ ID NO:42)  |
| A8           | F2*-Hyp-Ala-Ser-Phe-Gln-Ser-Ser-Lys(F2*)-NH-(mPEG 20,000) (SEQ ID NO:43)  |
| A9           | F1*-Gly-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys(F1*)-N(H) <br>(SEQ ID NO:44)       |
| A10          | Ac-lys(F8*)-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys(F8*)-N(H) <br>(SEQ ID NO:45)   |
| A11          | Ac-lys(F4*)-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys(F4*)-N(H) <br>(SEQ ID NO:46) |
| A12          | F2*-Gly-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys(F2*)-N(H) <br>(SEQ ID NO:47)     |

\* Structure of the F\* portion of the chemical structure is provided below in Table 4A. The F\* portion is covalently bound to the indicated amino acid residue to form an amide linkage.




**TABLE 4A.**


| No. | Fluorophore Structure  |
|-----|--|
| F1* | <p>Chemical structure of Fluorophore F1*: A bis-indole fluorophore with a central pyridine ring. The left indole has a 3-sulfonate group (HO<sub>3</sub>S-CH<sub>2</sub>-CH<sub>2</sub>-). The right indole has a 3-sulfonate group (-SO<sub>3</sub><sup>-</sup>-CH<sub>2</sub>-CH<sub>2</sub>-). The central pyridine ring has a 4-amide group (-C(=O)-NH-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-C(=O)-) and a wavy line indicating attachment to a polymer backbone.</p> |
| F2* | <p>Chemical structure of Fluorophore F2*: A bis-indole fluorophore with a central polyene chain. The left indole has a 3-sulfonate group (HO<sub>3</sub>S-CH<sub>2</sub>-CH<sub>2</sub>-). The right indole has a 3-sulfonate group (-SO<sub>3</sub><sup>-</sup>-CH<sub>2</sub>-CH<sub>2</sub>-). The central polyene chain has a wavy line indicating attachment to a polymer backbone.</p>   |
| F4* | <p>Chemical structure of Fluorophore F4*: A bis-indole fluorophore with a central polyene chain. The left indole has a 3-sulfonate group (HO<sub>3</sub>S-CH<sub>2</sub>-CH<sub>2</sub>-). The right indole has a 3-sulfonate group (-SO<sub>3</sub><sup>-</sup>-CH<sub>2</sub>-CH<sub>2</sub>-). The central polyene chain has a wavy line indicating attachment to a polymer backbone.</p>   |
| F8* | <p>Chemical structure of Fluorophore F8*: A bis-indole fluorophore with a central polyene chain. The left indole has a 3-sulfonate group (HO<sub>3</sub>S-CH<sub>2</sub>-CH<sub>2</sub>-). The right indole has a 3-sulfonate group (-SO<sub>3</sub><sup>-</sup>-CH<sub>2</sub>-CH<sub>2</sub>-). The central polyene chain has a wavy line indicating attachment to a polymer backbone.</p>   |

**[00129]** Exemplary prostate specific antigen activatable agents can include the following or a salt thereof:


- 49 -



- 50 -



- 51 -



- 52 -

[00130] The imaging agents disclosed herein can be formulated into a pharmaceutical composition suitable for administration to a subject, for example, an animal and/or a human. The pharmaceutical composition can include one or more imaging agents and one or more  
5 excipients, for example, a stabilizer in a physiologically relevant carrier.

[00131] For *in vivo* use, the compositions of the present invention can be provided in a formulation suitable for administration to a subject, for example, an animal or a human. Accordingly, the formulations include the agents together with a physiologically relevant carrier suitable for the desired form and/or dose of administration. The term, “physiologically  
10 relevant carrier” is understood to mean a carrier in which the agents are dispersed, dissolved, suspended, admixed and physiologically tolerable, i.e., can be administered to, in, or on the subject’s body without undue discomfort, or irritation, or toxicity. The preferred carrier is a fluid, preferably a liquid, more preferably an aqueous solution; however, carriers for solid formulations, topical formulations, inhaled formulations, ophthalmic formulations, and  
15 transdermal formulations are also contemplated as within the scope of the invention.

[00132] It is contemplated that the agents can be administered orally or parenterally. For parenteral administration, the agents can be administered intravenously, intramuscularly, cutaneously, percutaneously, subcutaneously, rectally, nasally, vaginally, and ocularly. Thus, the composition may be in the form of, *e.g.*, solid tablets, capsules, pills, powders including  
20 lyophilized powders, colloidal suspensions, microspheres, liposomes granulates, suspensions, emulsions, solutions, gels, including hydrogels, pastes, ointments, creams, plasters, irrigation solutions, drenches, osmotic delivery devices, suppositories, enemas, injectables, implants, sprays, or aerosols. The pharmaceutical compositions can be formulated according to conventional pharmaceutical practice (see, *e.g.*, Remington: The Science and Practice of  
25 Pharmacy, 20th edition, 2000, ed. A.R. Germark, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York).

[00133] It is understood that the formulation of the agents, the choice of mode of administration, the dosages of agents administered to the subject, and the timing between  
30 administration of the agents and imaging is within the level of skill in the art.

## II. APPLICATIONS

[00134] It is understood that prostate specific antigen activatable agents can be used in a variety of imaging and therapeutic applications.

### A. General Imaging Methods

5 [00135] The present invention provides methods for *in vitro* and *in vivo* imaging using the imaging agents disclosed herein. For a review of optical imaging techniques, see, e.g., Alfano et al., *Ann. NY Acad. Sci.* 820:248-270 (1997); Weissleder, *Nature Biotechnology* **19**, 316 - 317 (2001); Ntziachristos et al., *Eur. Radiol.* 13:195-208 (2003); Graves et al., *Curr. Mol. Med.* 4:419-430 (2004); Citrin et al., *Expert Rev. Anticancer Ther.* 4:857-864 (2004); Ntziachristos, 10 *Ann. Rev. Biomed. Eng.* 8:1-33 (2006); Koo et al., *Cell Oncol.* 28:127-139 (2006); and Rao et al., *Curr. Opin. Biotechnol.* 18:17-25 (2007).

[00136] Optical imaging includes all methods from direct visualization without use of any device and use of devices such as various scopes, catheters and optical imaging equipment, for example computer based hardware for tomographic presentations. The imaging agents are 15 useful with optical imaging modalities and measurement techniques including, but not limited to: endoscopy; fluorescence endoscopy; luminescence imaging; time resolved transmittance imaging; transmittance imaging; nonlinear microscopy; confocal imaging; acousto-optical imaging; photoacoustic imaging; reflectance spectroscopy; spectroscopy; coherence interferometry; interferometry; optical coherence tomography; diffuse optical tomography and 20 fluorescence mediated molecular tomography (continuous wave, time domain frequency domain systems and early photon), and measurement of light scattering, absorption, polarization, luminescence, fluorescence lifetime, quantum yield, and quenching.

[00137] An imaging system useful in the practice of the invention typically includes three basic components: (1) an appropriate light source for inducing excitation of the imaging agent, 25 (2) a system for separating or distinguishing emissions from light used for fluorophore excitation, and (3) a detection system. The detection system can be hand-held or incorporated into other useful imaging devices, such as intraoperative microscopes. Exemplary detection systems include an endoscope, catheter, tomographic system, hand-held imaging system, or an intraoperative microscope.

30 [00138] Preferably, the light source provides monochromatic (or substantially

- 54 -

monochromatic) light. The light source can be a suitably filtered white light, *i.e.*, bandpass light from a broadband source. For example, light from a 150-watt halogen lamp can be passed through a suitable bandpass filter commercially available from Omega Optical (Brattleboro, VT). Depending upon the system, the light source can be a laser. See, *e.g.*, Boas *et al.*, *Proc. Natl. Acad. Sci. USA* **91**:4887-4891, 1994; Ntziachristos *et al.*, *Proc. Natl. Acad. Sci. USA* **97**:2767-2772, 2000; and Alexander, *J. Clin. Laser Med. Surg.* **9**:416-418, 1991. Information on lasers for imaging can be found, for example, at Imaging Diagnostic Systems, Inc., Plantation, FL and various other sources. A high pass or bandpass filter can be used to separate optical emissions from excitation light. A suitable high pass or bandpass filter is commercially available from Omega Optical, Burlington, VT.

[00139] In general, the light detection system can be viewed as including a light gathering/image forming component and a light/signal detection/image recording component. Although the light detection system can be a single integrated device that incorporates both components, the light gathering/image forming component and light detection/image recording component are discussed separately.

[00140] A particularly useful light gathering/image forming component is an endoscope. Endoscopic devices and techniques which have been used for *in vivo* optical imaging of numerous tissues and organs, including peritoneum (Gahlen *et al.*, *J. Photochem. Photobiol. B* **52**:131-135, 1999), ovarian cancer (Major *et al.*, *Gynecol. Oncol.* **66**:122-132, 1997), colon and rectum (Mycek *et al.*, *Gastrointest. Endosc.* **48**:390-394, 1998; and Stepp *et al.*, *Endoscopy* **30**:379-386, 1998), bile ducts (Izuishi *et al.*, *Hepatogastroenterology* **46**:804-807, 1999), stomach (Abe *et al.*, *Endoscopy* **32**:281-286, 2000), bladder (Kriegmair *et al.*, *Urol. Int.* **63**:27-31, 1999; and Riedl *et al.*, *J. Endourol.* **13**:755-759, 1999), lung (Hirsch *et al.*, *Clin Cancer Res* **7**:5-220, 2001), brain (Ward, *J. Laser Appl.* **10**:224-228, 1998), esophagus, and head and neck regions can be employed in the practice of the present invention.

[00141] Other types of light gathering components are catheter-based devices, including fiber optics devices. Such devices are particularly suitable for intravascular imaging. See, *e.g.*, Tearney *et al.*, *Science* **276**:2037-2039, 1997; and *Circulation* **94**:3013, 1996.

[00142] Still other imaging technologies, including phased array technology (Boas *et al.*, *Proc. Natl. Acad. Sci. USA* **91**:4887-4891, 1994; Chance, *Ann. NY Acad. Sci.* **838**:29-45, 1998), optical tomography (Cheng *et al.*, *Optics Express* **3**:118-123, 1998; and Siegel *et al.*,

- 55 -

Optics Express 4:287-298, 1999), intravital microscopy (Dellian *et al.*, Br. J. Cancer 82:1513-1518, 2000; Monsky *et al.*, Cancer Res. 59:4129-4135, 1999; and Fukumura *et al.*, Cell 94:715-725, 1998), confocal imaging (Korlach *et al.*, Proc. Natl. Acad. Sci. USA 96:8461-8466, 1999; Rajadhyaksha *et al.*, J. Invest. Dermatol. 104:946-952, 1995; and Gonzalez *et al.*, J. Med. 5 30:337-356, 1999) and fluorescence molecular tomography (FMT) (Nziachristos *et al.*, Nature Medicine 8:757-760, 2002; U.S. Patent No. 6,615,063, PCT WO 03/102558, and PCT WO 03/079015) can be used with the imaging agents of the invention. Similarly, the imaging agents can be used in a variety of imaging systems, for example, (1) the IVIS® Imaging Systems: 100 Series, 200 Series (Xenogen, Alameda, CA), (2) SPECTRUM and LUMINA 10 (Xenogen, Alameda, CA), (3) the SoftScan® or the eXplore Optix™ (GE Healthcare, United Kingdom), (4) Maestro™ and Nuance™-2 Systems (CRi, Woburn, MA), (5) Image Station In-Vivo FX from Carestream Molecular Imaging, Rochester, NY (formerly Kodak Molecular Imaging Systems), (6) OV100, IV100 (Olympus Corporation, Japan), (7) Cellvizio Mauna Kea Technologies, France), (8) NanoSPECT/CT or HiSPECT (Bioscan, Washington, DC), (9) 15 CTLM® or LILA™ (Imaging Diagnostic Systems, Plantation, FL), (10) DYNOT™ (NIRx Medical Technologies, Glen Head, NY), and (11) NightOWL Imaging Systems by Berthold Technologies, Germany.

[00143] A variety of light detection/image recording components, e.g., charge coupled device (CCD) systems or photographic film, can be used in such systems. The choice of light 20 detection/image recording depends on factors including the type of light gathering/image forming component being used. It is understood, however, that the selection of suitable components, assembling them into an optical imaging system, and operating the system is within ordinary skill in the art.

[00144] For agents that have magnetic properties, MRI imaging well known in the art can 25 also be applied in the practice of the invention. For a review of MRI techniques see Westbrook, Handbook of MRI Technique, 2<sup>nd</sup> Edition, 1999, Blackwell Science. It is possible that images obtained, for example, by optical imaging and by magnetic resonance imaging can be co-registered or fused with one another to provide additional information about the item being imaged. Furthermore, multi-modality imaging systems (i.e., combined optical and MR 30 imaging systems) can be used to create combined optical MR images.

[00145] In addition, the compositions and methods of the present invention can be used



- 56 -

for other imaging compositions and methods.

[00146] In addition, the compositions and methods of the present invention can be used in combination with other imaging compositions and methods. For example, the agents of the present invention can be imaged by optical imaging protocols either alone or in combination  
5 with other traditional imaging modalities, such as, X-ray, computed tomography (CT), MR imaging, ultrasound, positron emission tomography (PET), and single photon computerized tomography (SPECT). For instance, the compositions and methods of the present invention can be used in combination with CT or MRI to obtain both anatomical and molecular information simultaneously, for example, by co-registration of with an image generated by  
10 another imaging modality. The compositions and methods of the present invention can also be used in combination with X-ray, CT, PET, ultrasound, SPECT and other optical and MR contrast agents or alternatively, the agents of the present invention may also include imaging agents, such as iodine, gadolinium atoms and radioactive isotopes, which can be detected using CT, PET, SPECT, and MR imaging modalities in combination with optical imaging. The  
15 imaging agents can be linked to or incorporated in the agents.

**(i) *In Vivo* Imaging Methods**

[00147] With respect to optical *in vivo* imaging, such a method comprises (a) administering to a subject one or more of the prostate specific antigen activatable agents described herein, (b) allowing sufficient time to permit the agent to distribute with the subject,  
20 and (c) detecting a signal emitted by the prostate specific antigen activatable agent. The signal emitted by the agent can be used to construct an image, for example, a tomographic image. The foregoing steps can be repeated at predetermined time intervals thereby to permit evaluation of the emitted signals of the prostate specific antigen activatable agents in the subject over time.

25 [00148] In another *in vivo* imaging method, the method comprises (a) administering to a subject one or more of the prostate specific antigen activatable agents described herein that contains a fluorochrome; (b) allowing sufficient time to permit the prostate specific antigen activatable agent to distribute within the subject; (c) exposing the subject to light of a wavelength absorbable by the fluorochrome, and (d) detecting a signal emitted by the prostate  
30 specific antigen activatable agent. The foregoing steps can be repeated at predetermined time intervals thereby to permit evaluation of the emitted signals of the prostate specific antigen

- 57 -

activatable agents in the subject over time. The illuminating and/or detecting steps (steps (c) and (d), respectively) can be performed using an endoscope, catheter, tomographic system, planar system, hand-held imaging system, goggles, or an intraoperative microscope.

5 [00149] Before or during these steps, a detection system can be positioned around or in the vicinity of a subject (for example, an animal or a human) to detect signals emitted from the subject. The emitted signals can be processed to construct an image, for example, a tomographic image. In addition, the processed signals can be displayed as images either alone or as fused (combined) images.

10 [00150] In addition, it is possible to practice an *in vivo* imaging method that selectively detects and images one, two or more molecular imaging probes, including the prostate specific antigen activatable agents simultaneously. In such an approach, for example, in step (a) noted above, two or more imaging probes whose signal properties are distinguishable from one another are administered to the subject, either at the same time or sequentially, wherein at least one of the molecular imaging probes is a prostate specific antigen activatable agent. The use of  
15 multiple probes permits the recording of multiple biological processes, functions or targets.

[00151] The subject may be a vertebrate, for example, a mammal, for example, a human. The subject may also be a non-vertebrate (for example, *C. elegans*, *Drosophila*, or another model research organism, etc.) used in laboratory research.

20 [00152] Information provided by such *in vivo* imaging approaches, for example, the presence, absence, or level of emitted signal can be used to detect and/or monitor a disease in the subject. Exemplary diseases include, without limitation cancer. In addition, *in vivo* imaging can be used to assess the effect of a compound or therapy by using the imaging agents, wherein the subject is imaged prior to and after treatment with the compound or therapy, and the corresponding signal/images are compared.

25 [00153] The prostate specific antigen activatable agents also can be used in *in vivo* imaging method where cells labeled with the prostate specific antigen activatable agent are administered to the recipient. The cells can be labeled with the prostate specific antigen activatable agents either *in vivo* or *ex vivo*. In the *ex vivo* approach, cells can be derived directly from a subject or from another source (e.g., from another subject, cell culture, etc.).  
30 The prostate specific antigen activatable agents can be mixed with the cells to effectively label the cells and the resulting labeled cells administered to the subject into a subject in step (a).

- 58 -

Steps (b)-(d) then are followed as described above. This method can be used for monitoring trafficking and localization of certain cell types, including T-cells, tumor cells, immune cells and stem cells, and other cell types. In particular, this method may be used to monitor cell-based therapies.

5    **[00154]**       It is understood that the formulation of the prostate specific antigen activatable agents, the choice of mode of administration, the dosages of prostate specific antigen activatable agents administered to the subject, and the timing between administration of the prostate specific antigen activatable agents and imaging is within the level of skill in the art.

10   **[00155]**       The foregoing methods can be used to determine a number of indicia, including tracking the localization of the prostate specific antigen activatable agent in the subject over time or assessing changes or alterations in the metabolism and/or excretion of the prostate specific antigen activatable agent in the subject over time. The methods can also be used to follow therapy for such diseases by imaging molecular events and biological pathways modulated by such therapy, including but not limited to determining efficacy, optimal timing, 15   optimal dosing levels (including for individual patients or test subjects), and synergistic effects of combinations of therapy.

20   **[00156]**       The methods and compositions of the invention can be used to help a physician or surgeon to identify and characterize areas of disease, such as dysplasia and cancer, to distinguish diseased from normal tissues, such as detecting specific regions of prostate cancer within an organ or other tissues that are difficult to detect using ordinary imaging techniques, and to further assess said tissues as candidates for particular treatment regimens, or gauge the prognosis such as likelihood of sepsis.

25   **[00157]**       The methods and compositions of the invention can also be used in the detection, characterization and/or determination of the localization of a disease, including early disease, the severity of a disease or a disease-associated condition, the staging of a disease, and/or 30   monitoring a disease. The presence, absence, or level of an emitted signal can be indicative of a disease state.

30   **[00158]**       The methods and compositions of the invention can also be used to monitor and/or guide various therapeutic interventions, such as surgical procedures, and monitoring drug therapy, including cell based therapies. The methods described herein can also be used to assess therapeutic efficacy of various treatment regimens, including but not limited to those

- 59 -

designed to reduce tumor acidosis and metastasis or various radiotherapeutics. The methods of the invention can also be used in prognosis of a disease or disease condition.

[00159] The methods and compositions described herein can, therefore, be used, for example, to detect and/or quantify the presence and/or localization of elevated prostate specific antigen in a subject, including humans, for instance in cancerous cells or tissues, and to detect and/or quantify the presence and/or localization of prostate specific antigen, including the presence of dysplastic areas within an organ. The methods and compositions described herein can also be used to detect and/or quantify prostate specific antigen associated with diseases, disorders and conditions, including but not limited to preneoplastic/neoplastic disease including areas at risk for acute occlusion (i.e., vulnerable plaques) in coronary and peripheral arteries, regions of expanding aneurysms, unstable plaque in carotid arteries, and ischemic areas. The methods and compositions of the invention can also be used in identification and evaluation of neoplasia, dysplasia, and cancer, such as prostate cancer. The methods and compositions can also be used for drug delivery and to monitor drug delivery, especially when drugs or drug-like molecules are chemically attached to the fluorescent probes. Exemplary drug molecules include chemotherapeutic and cytostatic agents and photodynamic agents including but not limited to Photofrin, Lutrin, Antrin, aminolevulinic acid, hypericin, benzoporphyrin derivative, and porphyrins.

[00160] In addition, the methods and compositions described herein can be used to image the enzymatically active prostate specific antigen levels in a subject. The method comprises administering to a subject (for example, a human or animal) an amount of one or more of the prostate specific antigen activatable agents described herein sufficient to facilitate prostate specific antigen imaging. After sufficient time to permit the agent to distribute within the animal or distribute within the area to be imaged, the presence and/or amount of the agent is determined. The presence and/or amount of the agent can then be used to create an image, for example, a tomographic image, representative of elevated positively charged cell surfaces within the tissues of the subject.

**(ii) *In Vitro Imaging Methods***

[00161] With respect to *in vitro* imaging, the imaging agents can be used in a variety of *in vitro* assays. For example, an exemplary *in vitro* imaging method comprises: (a) contacting a sample, for example, a biological sample, with one or more of the prostate specific antigen

- 60 -

activatable agents described herein; (b) allowing the agent(s) to interact with a biological target in the sample; (c) optionally, removing unbound agent; and (d) detecting a signal emitted from the agent thereby to determine whether the agent has been activated by or bound to the biological target. When the prostate specific antigen activatable agent comprises a  
5 fluorochrome, step (d) further comprises illuminating the sample with light of a wavelength absorbable by the fluorochrome to produce the emitted signal.

[00162] After an agent has been designed, synthesized, and optionally formulated, it can be tested *in vitro* by one skilled in the art to assess its biological and performance characteristics. For instance, different types of cells grown in culture can be used to assess the  
10 biological and performance characteristics of the agent. Cellular uptake, binding or cellular localization of the agent can be assessed using techniques known in the art, including, for example, fluorescent microscopy, FACS analysis, immunohistochemistry, immunoprecipitation, in situ hybridization and Forster resonance energy transfer (FRET) or fluorescence resonance energy transfer. By way of example, the agents can be contacted with a  
15 sample for a period of time and then washed to remove any free agents. The sample can then be viewed using an appropriate detection device such as a fluorescent microscope equipped with appropriate filters matched to the optical properties of a fluorescent agent. Fluorescence microscopy of cells in culture or scintillation counting is also a convenient means for determining whether uptake and binding has occurred. Tissues, tissue sections and other types  
20 of samples such as cytospin samples can also be used in a similar manner to assess the biological and performance characteristics of the agents. Other detection methods including, but not limited to flow cytometry, immunoassays, hybridization assays, and microarray analysis can also be used.

#### **B. Exemplary Imaging Methods**

25 [00163] One aspect of the invention provides a method of *in vivo* imaging, the method comprising: (a) administering to a subject a prostate specific antigen imaging agent; (b) allowing the agent to distribute within the subject; and (c) detecting a signal emitted by the prostate specific antigen imaging agent.

[00164] Another aspect of the invention provides a method of *in vivo* optical imaging, the  
30 method comprising: (a) administering to a subject a prostate specific antigen imaging agent, wherein the agent comprises a fluorochrome; (b) allowing the agent to distribute within the

- 61 -

subject; (c) exposing the subject to light of a wavelength absorbable by the fluorochrome; and (d) detecting a signal emitted by the agent.

[00165] Another aspect of the invention provides a method of *in vivo* imaging, wherein the signal emitted by the agent is used to construct an image. In other embodiments, the image is a tomographic image. In certain embodiments, the invention is a method of *in vivo* optical imaging, wherein steps (a) - (c) are repeated at predetermined time intervals thereby to permit evaluation of the emitted signals of the prostate specific antigen activatable agent in the subject over time. In certain embodiments, the invention is a method of *in vivo* optical imaging, wherein steps (a) - (d) are repeated at predetermined time intervals thereby to permit evaluation of the emitted signals of the prostate specific antigen activatable agents in the subject over time. In certain embodiments, the invention is a method of *in vivo* imaging, wherein the subject is an animal or a human. In certain embodiments, the invention is a method of *in vivo* imaging, wherein in step (a) two or more imaging probes whose signal properties are distinguishable from one another are administered to a subject, wherein at least one of the imaging probes is a prostate specific antigen activatable agent. In certain embodiments, the invention is a method of *in vivo* optical imaging, wherein the illuminating and detecting steps are performed using an endoscope, catheter, tomographic system, hand-held optical imaging system, or an intraoperative microscope.

[00166] Another aspect of the invention provides a method of *in vivo* imaging, wherein the presence, absence, or level of emitted signal is indicative of a disease state. In certain embodiments, the invention is a method of *in vivo* imaging, wherein the method is used to detect and/or monitor a disease. In certain embodiments, the disease is selected from the group consisting of dysplasia, neoplasia, prostate cancer and cancer. The agents described here are used for imaging sites of active PSA as a means for detecting prostate cancer.

[00167] Another aspect of the invention provides a method of *in vivo* imaging, wherein, in step (a), cells labeled with the prostate specific antigen activatable agent are administered to the subject. In other embodiments, the signal emitted by the prostate specific antigen activatable agent is used to monitor trafficking and localization of the cells.

[00168] Another aspect of the invention provides a method of imaging enzymatically active prostate specific antigen levels in a subject, the method comprising the steps of: (a) administering an agent to a subject; and (b) detecting the presence of the agent thereby to

- 62 -

produce an image representative of enzymatically active prostate specific antigen concentration. In certain embodiments, the invention is a method of treating a disease in a subject comprising administering to a subject, either systemically or locally, an agent, wherein the agent comprises a radiolabel that localizes in the disease area and delivers an effective dose of radiation.

5    **[00169]**       Another aspect of the invention provides an *in vitro* imaging method, the method comprising: (a) contacting a sample with an agent; (b) allowing the agent to bind to a biological target; (c) optionally removing unbound agent; and (d) detecting signal emitted from the agent thereby to determine whether the agent has been activated by or bound to the biological target. In other embodiments, the sample is a biological sample.

10   **[00170]**       In certain embodiments, the chemical modifying groups comprise a biologically active molecule, such as a drug or a radiotherapeutic moiety. In certain embodiments the biologically active molecule is linked to the agent through a linker that is cleavable through a biological or physical mechanism including but not limited to enzymatic, thermal, acid catalyzed or photochemical cleavage.

15   **[00171]**       In certain preferred embodiments, Q can be selected from a group consisting of (i) a substituted or unsubstituted aryl, (ii) a functionalized, substituted or unsubstituted heteroaryl, (iii) a functionalized, substituted or unsubstituted C<sub>1</sub>-C<sub>18</sub> alkyl, alkenyl, alkynyl, alkoxy, or thioalkyl group. In other embodiments, Q is absent.

20   **[00172]**       In certain embodiments, the chemical modifying moiety, M enhances the binding selectivity of the prostate specific antigen activatable agent for enzymatically active prostate specific antigen over other proteins.

25   **[00173]**       In certain embodiments, the chemical modifying moiety, M reduces the nonspecific enzymatic cleavage of the prostate specific antigen activatable agent. Furthermore, in other embodiments, the chemical modifying moiety, M reduces the nonspecific tissue accumulation of the prostate specific antigen activatable agent when administered to a live animal.

30   **[00174]**       In one aspect of the invention, prostate specific antigen activatable agents are fluorescent in the far-red or near-infrared spectral range upon activation.

30   **[00175]**       In certain embodiments, the prostate specific antigen activatable agent further comprises one or more chemical modifiers, independently, chemically linked to the prostate

- 63 -

specific antigen targeting moiety, L, and/or F or any combination thereof.

### C. Therapeutic Applications

[00176] Certain of the prostate specific antigen activatable agents described herein, for example, agents containing a radiolabel and drug molecule, can be used to ameliorate a symptom of, or treat, a particular disease or disorder. The method comprises (a) administering an amount of one or more the agents described herein sufficient to impart a therapeutic effect in the subject; and (b) permitting sufficient time for the agent to distribute within the subject or otherwise localize in a region of the subject to be treated and then, (c) depending on the therapeutic agent, optionally activating the agent to impart a therapeutic effect. For example, when the therapeutic agent is a radiolabel, no subsequent activation is required. However, when the therapeutic agent is a photoreactive agent, for example, a dye used in photodynamic therapy, the agent may be activated by exposing the agent to light having a wavelength that activates the agent. As a result, the agents can be used to treat a condition of interest, for example, a cancer, immune disorder, inflammatory disorder, vascular disorder and the like. Furthermore the agents can be used to inhibit dysplasia in an organ, or other region of interest in the subject, or reduce cancerous cell proliferation within a subject.

[00177] The invention will now be illustrated by means of the following examples, which are given for the purpose of illustration only and without any intention to limit the scope of the present invention.

### III. PHARMACEUTICAL COMPOSITIONS

[00178] Agents described herein may be formulated with one or more pharmaceutically acceptable carriers (additives) and/or diluents to provide a pharmaceutical composition. Exemplary pharmaceutical compositions comprise one or more agents and one or more pharmaceutically acceptable carriers. As described in detail below, the pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3)



- 64 -

topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally.

**[00179]** The phrase "pharmaceutically acceptable" is employed herein to refer to those  
5 compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

**[00180]** Pharmaceutically-acceptable carriers include a liquid or solid filler, diluent,  
10 excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve  
15 as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil  
20 and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and/or polyanhydrides; and (22)  
25 other non-toxic compatible substances employed in pharmaceutical formulations.

**[00181]** Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

30 **[00182]** Pharmaceutical compositions of this invention suitable for parenteral

- 65 -

administration comprise one or more agents of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

[00183] In certain embodiments, the invention provides a pharmaceutically acceptable composition suitable for administration to a subject comprising a prostate specific antigen imaging agent and a pharmaceutically acceptable excipient.

#### 10 IV. DEFINITIONS

[00184] To facilitate an understanding of the present invention, a number of terms and phrases are defined below.

[00185] The terms “a,” “an” and “the” as used herein mean “one or more” and include the plural unless the context is inappropriate.

15 [00186] As used herein, the term “effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results. Unless stated otherwise, an effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route. As used herein, the term “treating” includes any effect, *e.g.*, lessening, reducing, modulating, ameliorating or  
20 eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.

[00187] As used herein, the terms “patient” and “subject” refer to organisms to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (*e.g.*, murines, simians, equines, bovines, porcines, canines, felines, and the like),  
25 and most preferably includes humans.

[00188] Certain compounds described herein may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including *cis*- and *trans*-isomers, *R*- and *S*-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic

- 66 -

mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.

5     **[00189]**       The term “affinity” as used herein, refers to the ability of the prostate specific antigen activatable agent to bind to and/or be retained by a prostate specific antigen.

10    **[00190]**       As used herein, the term “functionality” is understood to mean a reactive functional group that can be further modified or derivatized with another molecule. In one aspect, the reactive functional group is an amine, carboxylic acid, carboxylic ester, halogen, hydrazine, hydroxylamine, nitrile, isonitrile, isocyanate, isothiocyanate, thiol, maleimide, azide, alkyne, tetrazolyl, phosphonate, alkene, nitro, and nitroso.

15    **[00191]**       The term “alkyl” is art-recognized, and includes saturated aliphatic groups, including straight-chain alkyl groups, and branched-chain alkyl groups. Moreover, the term “alkyl” (or “lower alkyl”) includes “substituted alkyls”, which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxy carbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxy, a phosphoryl, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or  
20    heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain may themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers,  
25    alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), -CN and the like. In certain embodiments, the alkyl is unsubstituted.

**[00192]**       The term “alkylene” refers to a diradical of an alkyl group. Exemplary alkylene groups include -CH<sub>2</sub>- and -CH<sub>2</sub>CH<sub>2</sub>.

30    **[00193]**       The term “heteroalkyl” is art-recognized and refers to saturated aliphatic groups, including straight-chain alkyl groups, and branched-chain alkyl groups where one of the


- 67 -

backbone carbon atoms has been replaced with a heteroatom, such as O, S, or N. Exemplary heteroalkyl groups include  $-\text{CH}_2\text{-O-CH}_3$  and  $-\text{CH}_2\text{CH}_2\text{-O-CH}_3$ .

**[00194]** The term “heteroalkylene” refers to a diradical of an heteroalkyl group. Exemplary heteroalkylene groups include  $-\text{CH}_2\text{-O-CH}_2-$  and  $-\text{CH}_2\text{CH}_2\text{-O-CH}_2-$ .

- 5 **[00195]** The term “aryl” is art-recognized and refers to 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as “heteroaryl” or “heteroaromatics.” The aromatic ring may be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties,  $-\text{CF}_3$ ,  $-\text{CN}$ , or the like. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is aromatic, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
- 10
- 15

**[00196]** The term “arylene” as used herein refers to a divalent radical of an aromatic group. Arylene may be optionally substituted as described for aryl, or as otherwise indicated.


- 20 An exemplary arylene group is .

- [00197]** As used herein, the terms “heterocyclic” and “heterocyclyl” refer to an aromatic or nonaromatic ring containing one or more heteroatoms. The heteroatoms can be the same or different from each other. Examples of heteroatoms include, but are not limited to nitrogen, oxygen and sulfur. Aromatic and nonaromatic heterocyclic rings are well-known in the art. Some nonlimiting examples of aromatic heterocyclic rings include pyridine, pyrimidine, indole, purine, quinoline and isoquinoline. Nonlimiting examples of nonaromatic heterocyclic compounds include piperidine, piperazine, morpholine, pyrrolidine and pyrazolidine. Examples of oxygen containing heterocyclic rings include, but not limited to furan, oxirane, 2H-pyran, 4H-pyran, 2H-chromene, and benzofuran. Examples of sulfur-containing
- 25

- 68 -

heterocyclic rings include, but are not limited to, thiophene, benzothiophene, and parathiazine. Examples of nitrogen containing rings include, but not limited to, pyrrole, pyrrolidine, pyrazole, pyrazolidine, imidazole, imidazoline, imidazolidine, pyridine, piperidine, pyrazine, piperazine, pyrimidine, indole, purine, benzimidazole, quinoline, isoquinoline, triazole, and triazine. Examples of heterocyclic rings containing two different heteroatoms include, but are not limited to, phenothiazine, morpholine, parathiazine, oxazine, oxazole, thiazine, and thiazole. The heterocyclic (or heterocyclyl) ring is optionally further substituted at one or more ring positions with, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, amino, nitro, sulfhydryl, imino, amido, carboxylic acid, -C(O)alkyl, -CO<sub>2</sub>alkyl, carbonyl, carboxyl, alkylthio, sulfonyl, sulfonamido, sulfonamide, ketone, aldehyde, ester, aryl or heteroaryl moieties, -CF<sub>3</sub>, -CN, or the like.

**[00198]** The terms “amine” and “amino” are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that may be represented by the general formulas:



15

wherein R<sup>50</sup>, R<sup>51</sup>, R<sup>52</sup> and R<sup>53</sup> each independently represent a hydrogen, an alkyl, an alkenyl, -(CH<sub>2</sub>)<sub>m</sub>-R<sup>61</sup>, or R<sup>50</sup> and R<sup>51</sup>, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R<sup>61</sup> represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8. In certain embodiments, only one of R<sup>50</sup> or R<sup>51</sup> may be a carbonyl, e.g., R<sup>50</sup>, R<sup>51</sup> and the nitrogen together do not form an imide. In other embodiments, R<sup>50</sup> and R<sup>51</sup> (and optionally R<sup>52</sup>) each independently represent a hydrogen, an alkyl, an alkenyl, or -(CH<sub>2</sub>)<sub>m</sub>-R<sup>61</sup>.

20

The terms “alkoxy” or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxy groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxy, such as may be represented by one of -O-alkyl, -O-alkenyl,

25

- 69 -

-O-alkynyl, -O-(CH<sub>2</sub>)<sub>m</sub>-R<sup>61</sup>, where m and R<sup>61</sup> are described above.

[00199] The term “substituted” refers to a group in which one or more hydrogen atoms are independently replaced with the same or different substituent(s). Exemplary substituents include, but are not limited to, halogen, alkyl, haloalkyl, oxo, alkoxy, thiol, thioether, cyano, ester, ketone, amide, sulfonamide, carboxylate, carboxylic acid, aryl, aralkyl, alkenyl, alkynyl, 5 alkylene-amide, etc.

[00200] As used herein, the term “pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (*e.g.*, acid or base) of a compound of the present invention which, upon administration to a subject, is capable of providing a compound of this invention 10 or an active metabolite or residue thereof. As is known to those of skill in the art, “salts” of the compounds of the present invention may be derived from inorganic or organic acids and bases. Examples of acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene- 15 2-sulfonic, benzenesulfonic acid, and the like. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

[00201] Examples of bases include, but are not limited to, alkali metals (*e.g.*, sodium) 20 hydroxides, alkaline earth metals (*e.g.*, magnesium), hydroxides, ammonia, and compounds of formula NW<sub>4</sub><sup>+</sup>, wherein W is C<sub>1-4</sub> alkyl, and the like.

[00202] Examples of salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, 25 fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include anions of the compounds of the 30 present invention compounded with a suitable cation such as Na<sup>+</sup>, NH<sub>4</sub><sup>+</sup>, and NW<sub>4</sub><sup>+</sup> (wherein W

- 70 -

is a C<sub>1-4</sub> alkyl group), and the like.

[00203] For therapeutic use, salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or  
5 purification of a pharmaceutically acceptable compound.

[00204] Throughout the description, where compositions and kits are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions and kits of the present invention that consist essentially of, or consist of, the  
10 recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.

## V. EXAMPLES

[00205] The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of  
15 certain aspects and embodiments of the present invention, and are not intended to limit the invention.


### EXAMPLE 1: EXEMPLARY SYNTHESSES OF PSA ACTIVATABLE AGENTS

[00206] The compounds of the present invention can be synthesized from readily available starting materials following standard methods and procedures. The following non-  
20 limiting examples demonstrate the synthesis of exemplary fluorescent prostate specific antigen activatable agents. Representative materials and methods that may be used in preparing the materials of the invention are described further below. Unless otherwise stated, all chemicals and solvents (reagent grade) are used as commercially obtained without further purification. Synthesized compounds are characterized and purified by HPLC or ion-exchange column  
25 chromatography.


[00207] The *N*-hydroxysuccinimide ester (ie., NHS ester) of a fluorophore from Table 3 refers to the compound in which the carboxylic acid group of the fluorophore has been replaced with a *N*-hydroxysuccinimide ester. For example, the *N*-hydroxysuccinimide ester of

- 71 -

fluorophore F2 has the following chemical structure:



[00208] The abbreviation “EDC” refers to 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. The abbreviation “HOBt” refers to hydroxybenzotriazole. The abbreviation Y-  
 5 mPEG amine refers to the following compound:



### **Part I: General Procedures:**

[00209] **General Method A for Peptide Conjugation.** A solution of fluorophore-NHS ester (~3  $\mu\text{mol}$ ) in dimethylformamide (DMF) was added to a solution of oligopeptide (1  $\mu\text{mol}$ )  
 10 in DMF (1 mL). After the reaction was complete, as judged by HPLC, the solution was diluted with aqueous sodium bicarbonate to hydrolyze excess fluorophore-NHS ester. The desired product was then isolated by preparatory HPLC.

[00210] **General Method B for mPEG Amine Coupling.** To a solution of fluorophore-labeled peptide and mPEG amine (1.5 equiv) in DMF was added HOBt (1 equiv), N-methylmorpholine (2 equiv), and EDC (1.5 equiv). After the reaction was complete, the  
 15 reaction mixture was diluted with water and the desired product isolated by ion-exchange column chromatography.

### **Part II: Synthesis of PSA Activatable Agent A1**

20 [00211] Oligopeptide, SEQ 1 from Table 1 above, was conjugated with the N-hydroxysuccinimide ester of fluorophore F2 using general method A. The resulting crude product was purified by preparatory HPLC.



- 72 -

### **Part III: Synthesis of PSA Activatable Agent A3**

[00212] Oligopeptide, SEQ 3 from Table 1 above, was conjugated with the NHS ester of F2 using general method A. After purification by preparatory HPLC, the conjugate was coupled with mPEG amine, ~20 kDa, using general method B. The resulting product was purified through ion-exchange column chromatography.

### **EXAMPLE 2: SYNTHESIS OF PSA ACTIVATABLE AGENT A5**

[00213] Oligopeptide, SEQ 4 from Table 1 above, was conjugated with the NHS ester of F8 using general method A from Example 1. After purification by preparatory HPLC, the conjugate was coupled with mPEG amine, ~10 kDa, using general method B from Example 1. The resulting product was purified through ion-exchange column chromatography.

### **EXAMPLE 3: SYNTHESIS OF PSA ACTIVATABLE AGENT A10**

[00214] Oligopeptide, SEQ 5 from Table 1 above, was conjugated with the NHS ester of F8 using general method A from Example 1. After purification by preparatory HPLC, the conjugate was coupled with Y-mPEG amine, ~40 kDa, using general method B from Example 1. The resulting product was purified through ion-exchange column chromatography.

### **EXAMPLE 4: SYNTHESIS OF PSA ACTIVATABLE AGENT A12**

[00215] Oligopeptide, SEQ 13 from Table 1 above, was conjugated with the NHS ester of F2 using general method A from Example 1. After purification by preparatory HPLC, the conjugate was coupled with Y-mPEG amine, ~40 kDa, using general method B from Example 1. The resulting product was purified through ion-exchange column chromatography.

### **EXAMPLE 5: PROSTATE SPECIFIC ANTIGEN ACTIVATABLE AGENTS ARE CLEAVED BY ENZYMATICALLY ACTIVE PSA *IN VITRO***

[00216] This example demonstrates that the prostate specific antigen activatable agents described herein are cleaved by enzymatically active prostate specific antigen *in vitro*. Test agent (compound A10 - 0.5  $\mu$ M final concentration of agent) was activated in the presence of active PSA (0.1  $\mu$ M final concentration of activated enzyme) but not complexed PSA, in the optimized buffer (TCNB or 50 mM Tris, 10 mM  $\text{CaCl}_2$ , 150 mM NaCl, 0.05% Brij-35, pH 7.5) for each enzyme. Kinetic fluorescence readings were performed in a Gemini fluorescence plate

- 73 -

reader at different times after adding the enzyme.

[00217] In this experiment, fluorescence is only associated with the test agents (compound A10) in the presence of active PSA described herein. The results, shown in Figure 1, demonstrate *in vitro* activation of the prostate specific antigen activatable agents, such as compound A10 in the presence of active PSA.

**EXAMPLE 6: IN VIVO IMAGING OF PROSTATE CANCER USING PROSTATE SPECIFIC ANTIGEN ACTIVATABLE AGENTS**

[00218] As depicted in Figure 2A, imaging studies were performed in human prostate PSA<sup>+</sup> LNCaP tumor-bearing male Nu/Nu mice. The mice were injected intravenously with 2 nmoles of test agent (compound A10) and were imaged 6 hours later on the FMT2500 (PerkinElmer Inc., Waltham, MA) (FMT 2D for epifluorescence, FMT 3D for tomography) in reflectance and tomographic modes, and on the IVIS Spectrum (PerkinElmer Inc., Waltham, MA). Sites of active PSA are detected in the same locations for both reflectance and tomographic imaging, thereby demonstrating the ability of the agent to detect enzymatically active PSA *in vivo*.

**EXAMPLE 7: SPECIFICITY OF PROSTATE SPECIFIC ANTIGEN ACTIVATABLE AGENTS IN VIVO**

[00219] Imaging studies were performed in LNCaP tumors (PSA+) and PC3 (PSA-) tumors tumor-bearing male Nu/Nu mice. The mice were injected intravenously with 2 nmoles of compound A10 and imaged 24 hours later on the FMT2500 (PerkinElmer Inc., Waltham, MA). Tumor fluorescence from positive and control mice was quantified and plotted. Figure 2B demonstrates the specificity the prostate specific antigen activatable agents have for tumors containing enzymatically active PSA over PSA negative tumors *in vivo*.

**INCORPORATION BY REFERENCE**

[00220] All publications, patents, and patent applications cited herein are hereby expressly incorporated by reference in their entirety and for all purposes to the same extent as if each was so individually denoted.

- 74 -


### EQUIVALENTS

[00221] The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing  
5 description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.

- 75 -

What is claimed is:

- 1 1. A prostate specific antigen (PSA) activatable agent comprising:
  - 2 a. a prostate specific antigen targeting moiety comprising an enzymatically
  - 3 cleavable oligopeptide sequence; and
  - 4 b. two or more fluorophore moieties, with or without a quencher, chemically
  - 5 linked, optionally through a linker (L) moiety to the prostate specific antigen
  - 6 targeting moiety, and
  - 7 c. an optional modifier, M, chemically linked to the prostate specific antigen
  - 8 targeting moiety.
- 1 2. The agent of claim 1, wherein the prostate specific antigen activatable agent is represented
- 2 by Formula (I) or a salt thereof:




- 5 wherein
- 6 F is a near infrared fluorophore or quencher;
- 7 L is a bond or linker;
- 8 M is a modifier, attached to either the C or N terminus, or both, of the oligopeptide; and
- 9 n represents independently 0 or 1, providing that there is at least one occurrence of M.
- 1 3. The agent of claim 1 or 2, wherein the fluorophore or quencher bears a plurality of
- 2 chemical modifying moieties.
- 1 4. The agent of any one of claims 1-3, wherein the agent, upon activation by PSA, is
- 2 fluorescent in the far-red or near-infrared wavelengths.
- 1 5. The agent of claim 2, wherein the PSA-cleavable oligopeptide is a radical of one of the
- 2 following oligopeptides:
  - 3 a. Ac-Lys-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys-NH<sub>2</sub> (SEQ ID NO:1)
  - 4 b. Gly-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys-NH<sub>2</sub> (SEQ ID NO:2)
  - 5 c. Gly-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:3)
  - 6 d. Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:4)

- 76 -

- 7 e. Ac-Lys-Hyp-Ser-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:5)
- 8 f. Ac-Lys-Hyp-Ala-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:6)
- 9 g. Gly-Ser-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:7)
- 10 h. Ac-Lys-Ala-Ser-Phe-Gln-Ser-Leu-Lys (SEQ ID NO:9)
- 11 i. Hyp-Ser-Chg-Gln-Ser-Lys (SEQ ID NO:10)
- 12 j. Ac-Lys-Hyp-Ser-Ser-Phe-Gln-Ser-Ser-Lys (SEQ ID NO:11)
- 13 k. Gly-Ala-Ser-Chg-Gln-Ser-Ser-Lys (SEQ ID NO:12).
- 1 6. The agent of any one of claims 1-5, wherein M is hydrogen, sulfonate, polysulfonate,  
2 sulfonamide, sulfoxide, sulfone, carboxylate, ketone, phosphonate, phosphate,  
3 iminodiacetate, or a radical of: an alcohol, cysteic acid, an amine, ethylenediamine  
4 tetraacetic acid, diethylenetriamine pentaacetic acid, tetraazacyclododecane tetraacetic acid,  
5 an amino acid or polyamino acid, oligo- or polyethylene glycol, quaternary ammonium ion,  
6 a sugar, glucosamine, galactosamine, mannosamine, polyethylene glycol (PEG), branched  
7 polypropylene glycol, polypropylene glycol, a graft copolymer of poly-lysine and  
8 methoxypolyethyleneglycol, a peptide, a lipid, a fatty acid, palmitate, a phospholipid, a  
9 phospholipid-PEG conjugate, a carbohydrate, polyvinylpyrrolidone, an iron oxide  
10 nanoparticle, naphthylalanine, phenylalanine, 3,3-diphenylpropylamine, taurine, a  
11 phosphonate, a phosphate, a carboxylate, or a polycarboxylate.
- 1 7. The agent of any one of claims 1-6, wherein L is a diradical of a moiety selected from the  
2 group consisting of glycine, alanine,  $\beta$ -alanine,  $-\text{NH}-(\text{CH}_2)_n-\text{C}(=\text{O})-$  where n is an integer  
3 from 1 to 8, 4-aminomethylbenzoic acid, cysteic acid, glutamic acid, amino-polyethylene  
4 glycol-carboxylic acid, amino-polyethylene glycol amine, ethylenediamine,  
5 propylenediamine, spermidine, spermine, hexanediamine, a diamine-amino acid,  
6 homolysine, lysine, ornithine, diaminobutyric acid, diaminopropionic acid, succinic acid,  
7 glutaric acid, suberic acid, adipic acid, amide, triazole, urea, and thiourea.
- 1 8. The agent of any one of claims 1-7, wherein the chemical modifier(s) M improves the  
2 pharmacokinetics of the agent when administered to a live animal.
- 1 9. The agent of claim 2, wherein F-L taken together are represented by Formula B or C,  
2 wherein Formula B is represented by:

- 77 -



(B)

or a salt thereof, wherein:

X is independently selected from the group consisting of  $C(CH_2Y_1)(CH_2Y_2)$ , O, S, and Se;

$Y_1$  and  $Y_2$  are independently selected from the group consisting of H,  $C_1$ - $C_{20}$  aliphatic group, and a  $C_1$ - $C_{20}$  aliphatic group substituted with  $-OR^*$ ,  $N(R^*)_2$  or  $-SR^*$ ;

W represents a benzo-condensed, a naphtho-condensed, or a pyrido-condensed ring;

$R^*$  is alkyl;

$R_1$  is selected from the group consisting of  $-(CH_2)_xCH_3$ ,  $-(CH_2)_nSO_3^-$ , and  $-(CH_2)_nSO_3H$ , wherein x is an integer selected from 0 to 6 and n is an integer selected from 2 to 6;


$R_4$  is selected from the group consisting of  $-(CH_2)_xCH_3$ ,  $-(CH_2)_nSO_3^-$ , and  $-(CH_2)_nSO_3H$ , wherein x is an integer selected from 0 to 6 and n is an integer selected from 2 to 6;

$R_2$  and  $R_3$  are independently selected from the group consisting of H, carboxylate, carboxylic acid, carboxylic ester, amine, amide, sulfonamide, hydroxyl, alkoxy, a sulphonic acid moiety, and a sulphonate moiety;

Q is  $-aryl-C(O)N(R^{**})-(C_{1-8} \text{ alkylene})C(O)-$  where the arylene group is covalently bonded to the alkenylene core of Formula B; and

$R^{**}$  is hydrogen or alkyl; and

Formula C is represented by:




(C)

or a salt thereof, wherein:

- 78 -

- 29 X is independently selected from the group consisting of  $C(CH_2K_1)(CH_2K_2)$ , O, S and  
 30 Se;
- 31  $K_1$  and  $K_2$  are independently H or  $C_1$ - $C_{20}$  aliphatic; or  $K_1$  and  $K_2$  together are part of a  
 32 substituted or unsubstituted carbocyclic or heterocyclic ring;
- 33  $Y_1$  and  $Y_2$  are each independently a benzo-condensed ring, a naphtha-condensed ring, or  
 34 a pyrido-condensed ring;
- 35  $n_1$  is 1, 2, or 3;
- 36  $R_2$ ,  $R_{11}$  and  $R_{12}$  are independently H, halogen, alkyl, alkoxy, aryloxy, aryl, a sulfonate,  
 37 an iminium ion, or any two adjacent  $R_{12}$  and  $R_{11}$  substituents, when taken in combination, form  
 38 a 4-, 5-, or 6-membered carbocyclic ring optionally substituted one or more times by  $C_1$ - $C_6$   
 39 alkyl, halogen, or -S-alkyl;
- 40  $R_1$  and  $R_{13}$  are  $-(CH_2)_xCH_3$ , when x is an integer selected from 0 to 6; or  $R_1$  and  $R_{13}$  are  
 41 independently  $-(CH_2)_nSO_3^-$  or  $-(CH_2)_nSO_3H$  when n is an integer selected from 2 to 6;
- 42  $R_3$ ,  $R_4$  and  $R_5$  are independently selected from the group consisting of H, carboxylate,  
 43 carboxylic acid, carboxylic ester, amine, amide, sulfonamide, hydroxyl, alkoxy, a sulphonic  
 44 acid moiety, and a sulphonate moiety;
- 45  $R_6$  is unsubstituted  $C_1$ - $C_{20}$  aliphatic, unsubstituted aryl, or unsubstituted alkylaryl;  
 46  $R_7$  is H, unsubstituted  $C_1$ - $C_{20}$  aliphatic, unsubstituted aryl, or unsubstituted alkylaryl,  
 47 wherein  $R_7$  is optionally substituted with halogen; or
- 48  $R_6$  and  $R_7$ , taken together form a 4-, 5-, 6- or 7-membered heterocyclic ring optionally  
 49 substituted with halogen;
- 50 W is absent or is a group selected from the group consisting of  $-SO_2NR_6-Q-CHR_7-$ ,  $-O-$ ,  
 51  $-C(O)O-$ , and  $-C(O)N(H)-$ ; and
- 52  $h = 0-70$ ;  $k = 0$  or 1;  $d = 0-12$ ;  $m = 0-12$ ;  $p = 0-12$ .

1 10. A prostate specific antigen (PSA) activatable agent represented by Formula II:



(II)


4 or a salt thereof, wherein:

- 79 -

R<sup>1</sup> is hydrogen, -(C<sub>1-6</sub> alkylene)-methoxypolyethylene glycol, or -(C<sub>1-6</sub> alkylene)-N(R\*)C(O)-(C<sub>1-6</sub> alkylene)-N(-(C<sub>1-6</sub> alkylene)-methoxypolyethylene glycol)C(O)-(C<sub>1-6</sub> alkylene)-methoxypolyethylene glycol;

R\* is hydrogen or unsubstituted C<sub>1-6</sub> alkyl;

F represents independently for each occurrence structural Formula IIa or IIb:



(IIa)

wherein:

R<sup>2</sup> represents independently for each occurrence hydrogen or unsubstituted C<sub>1-6</sub> alkyl, or two adjacent occurrences of R<sup>2</sup> are taken together with the atoms to which they are attached to form a 5- or 6-membered carbocyclic ring;

R<sup>3</sup> is hydrogen or unsubstituted C<sub>1-6</sub> alkyl, or R<sub>3</sub> and an adjacent occurrence of R<sup>2</sup> are taken together with the atoms to which they are attached to form a 5- or 6-membered carbocyclic ring;

R<sup>4</sup> is hydrogen or unsubstituted C<sub>1-6</sub> alkyl;

R<sup>5</sup> represents independently for each occurrence unsubstituted C<sub>1-6</sub> alkyl, unsubstituted C<sub>1-6</sub> alkyl-SO<sub>3</sub><sup>-</sup> M<sup>+</sup>, or unsubstituted C<sub>1-6</sub> alkyl-SO<sub>3</sub>H;

R<sup>6</sup> and R<sup>7</sup> each represent independently for each occurrence hydrogen, -SO<sub>3</sub>H, or -SO<sub>3</sub><sup>-</sup> M<sup>+</sup>;

M is a monovalent cation or absent;

n is 1, 2, or 3;

W represents a benzo-condensed, a naphtho-condensed, or a pyrido-condensed ring;


X represents independently for each occurrence C(CH<sub>2</sub>Y<sub>1</sub>)(CH<sub>2</sub>Y<sub>2</sub>), O, or S; and

Y<sub>1</sub> and Y<sub>2</sub> are independently hydrogen or unsubstituted C<sub>1-6</sub> alkyl; and

Formula IIb is represented by:



- 80 -



(IIb)

wherein:

$R^{1b}$  and  $R^{3b}$  each represent independently unsubstituted  $C_{1-6}$  alkyl, unsubstituted  $C_{1-6}$  alkyl- $SO_3^- M^+$ , or unsubstituted  $C_{1-6}$  alkyl- $SO_3H$ ;

$R^{2b}$  each represents independently for each occurrence methyl, ethyl, or propyl;

$R^{4b}$  and  $R^{5b}$  each represent independently for each occurrence occurrence hydrogen,  $-SO_3H$ , or  $-SO_3^- M^+$ ;

$R^{6b}$  is hydrogen or  $C_{1-6}$  unsubstituted alkyl;


M is a monovalent cation or absent;

W represents a benzo-condensed, a naphtho-condensed, or a pyrido-condensed ring;


Z is arylene;

$X^1$  is unsubstituted  $C_{1-8}$  alkylene; and

the PSA-cleavable oligopeptide is one of the following:










(SEQ ID NO:14)




(SEQ ID NO:15)

- 81 -




- 82 -


53




54




55




56




57









58



59




- 83 -



- 1 11. The agent of claim 10, wherein F is represented by structural Formula IIa.
- 1 12. The agent of claim 11, wherein W represents a benzo-condensed ring.
- 1 13. The agent of claim 10, wherein F is represented by the following structural formula:

- 84 -



wherein:

$R^2$  represents independently for each occurrence hydrogen or unsubstituted  $C_{1-6}$  alkyl, or two adjacent occurrences of  $R^2$  are taken together with the atoms to which they are attached to form a 5- or 6-membered carbocyclic ring;

$R^3$  is hydrogen or unsubstituted  $C_{1-6}$  alkyl, or  $R^3$  and an adjacent occurrence of  $R^2$  are taken together with the atoms to which they are attached to form a 5- or 6-membered carbocyclic ring;

$R^4$  is hydrogen or unsubstituted  $C_{1-6}$  alkyl;

$R^5$  represents independently for each occurrence unsubstituted  $C_{1-6}$  alkyl- $SO_3^- M^+$  or unsubstituted  $C_{1-6}$  alkyl- $SO_3H$ ;

M is a monovalent cation or absent;

n is 1, 2, or 3; and

X is  $C(CH_3)_2$  or  $C(CH_2CH_3)_2$ .


14. The agent of any one of claims 10-13, wherein  $R^2$  and  $R^3$  are hydrogen.

15. The agent of any one of claims 10-14, wherein  $R^4$  is methyl.


16. The agent of any one of claims 10-15, wherein n is 2 or 3.

17. The agent of any one of claims 10-16, wherein X is  $C(CH_3)_2$ .


18. The agent of claim 10, wherein F is represented by one of the following structural formulae:




- 85 -




4




5



6



7




8

1 19. The agent of claim 10, wherein F is represented by structural Formula IIb.

1 20. The agent of claim 19, wherein W represents a benzo-condensed ring.

1 21. The agent of claim 10, wherein F is represented by the following structural Formula:

- 86 -



wherein:

$R^{1b}$  and  $R^{3b}$  each represent independently unsubstituted  $C_{1-6}$  alkyl, unsubstituted  $C_{1-6}$  alkyl- $SO_3^- M^+$ , or unsubstituted  $C_{1-6}$  alkyl- $SO_3H$ ;

$R^{2b}$  represents independently for each occurrence methyl or ethyl;

$R^{6b}$  is hydrogen or methyl;

M is a monovalent cation or absent;

Z is arylene; and


$X^1$  is unsubstituted  $C_{1-6}$  alkylene.

22. The agent of any one of claims 19-21, wherein  $R^{1b}$  and  $R^{3b}$  each represent independently unsubstituted  $C_{1-6}$  alkyl- $SO_3^- M^+$  or unsubstituted  $C_{1-6}$  alkyl- $SO_3H$ .

23. The agent of any one of claims 19-22, wherein  $R^{2b}$  is methyl.

24. The agent of any one of claims 19-23, wherein  $R^{6b}$  is hydrogen.

25. The agent of any one of claims 19-24, wherein Z is a 6-membered heteroaromatic diradical.




26. The agent of any one of claims 19-24, wherein Z is .

27. The agent of any one of claims 19-26, wherein  $X^1$  is  $-(CH_2)_4-$ ,  $-(CH_2)_5-$ , or  $-(CH_2)_6-$ .

28. The agent of claim 10, wherein F is represented by one of the following structural formulae:

- 87 -

3




4

5

- 1 29. The agent of any one of claims 10-28, wherein the PSA-cleavable oligopeptide is one of  
 2 the following:


3




(SEQ ID NO:14)




- 88 -



(SEQ ID NO:15)




(SEQ ID NO:17)



(SEQ ID NO:33).



30. The agent of any one of claims 10-29, wherein  $R^1$  is  $-(C_{1-6} \text{ alkylene})-N(R^*)C(O)-(C_{1-6} \text{ alkylene})-N(-(C_{1-6} \text{ alkylene})\text{-methoxypolyethylene glycol})C(O)-(C_{1-6} \text{ alkylene})\text{-methoxypolyethylene glycol}$ .




31. The agent of any one of claims 10-29, wherein  $R^1$  is
32. The agent of any one of claims 10-31, wherein the methoxypolyethylene glycol has a weight average molecular weight of about 5,000 g/mol to about 30,000 g/mol.
33. The agent of any one of claims 10-31, wherein the methoxypolyethylene glycol has a weight average molecular weight of about 20,000 g/mol.
34. The agent of any one of claims 10-29, wherein  $R^1$  is hydrogen.
35. The agent of claim 1, wherein the agent is one of the agents in Table 4 or a salt thereof.

- 89 -


- 1 36. The agent of claim 1, wherein the agent is one of the following or a salt thereof:



- 90 -



56



7

- 91 -

- 1 37. A pharmaceutical composition comprising an agent of any one of claims 1-36 and a  
2 pharmaceutically acceptable excipient.
- 1 38. A method of *in vivo* imaging, comprising:  
2 (a) administering to a subject an agent of any one of claims 1-36;  
3 (b) allowing the agent to distribute within the subject; and  
4 (c) detecting a signal emitted by the prostate specific antigen activatable agent.
- 1 39. A method of *in vivo* optical imaging, comprising:  
2 (a) administering to a subject an agent of any one of claims 1-36, wherein the agent  
3 comprises a fluorochrome;  
4 (b) allowing the agent to distribute within the subject;  
5 (c) exposing the subject to light of a wavelength absorbable by the fluorochrome; and  
6 (d) detecting a signal emitted by the agent.
- 1 40. The method of claim 38 or 39, wherein the signal emitted by the agent is used to construct  
2 an image.
- 1 41. The method of claim 38 or 39, wherein the image is a tomographic image.
- 1 42. The method of claim 38, wherein steps (a) - (c) are repeated at predetermined time  
2 intervals thereby to permit evaluation of the emitted signals of the prostate specific  
3 antigen activatable agent in the subject over time.
- 1 43. The method of claim 39, wherein steps (a) - (d) are repeated at predetermined time  
2 intervals thereby to permit evaluation of the emitted signals of the prostate specific  
3 antigen activatable agent in the subject over time.
- 1 44. The method of claim 38 or 39, wherein the subject is an animal or a human.
- 1 45. The method of claim 38 or 39, wherein in step (a) two or more imaging probes whose  
2 signal properties are distinguishable from one another are administered to a subject,  
3 wherein at least one of the imaging probes is a prostate specific antigen activatable agent.
- 1 46. The method of claim 38, wherein the illuminating and detecting steps are performed using  
2 an endoscope, catheter, tomographic system, hand-held optical imaging system, or an  
3 intraoperative microscope.

- 92 -

- 1 47. The method of claim 38 or 39, wherein the presence, absence, or level of emitted signal is  
2 indicative of a disease state.
- 1 48. The method of claim 38 or 39, wherein the method is used to detect and/or monitor a  
2 disease.
- 1 49. The method of claim 48, wherein the disease is selected from the group consisting of  
2 dysplasia, neoplasia, and cancer.
- 1 50. The method of claim 38 or 39, wherein, in step (a), cells labeled with the prostate specific  
2 antigen activatable agent are administered to the subject.
- 1 51. The method of claim 50, wherein a signal emitted by the prostate specific antigen  
2 activatable agent is used to monitor trafficking and localization of the cells.
- 1 52. A method of imaging prostate cancer in a subject, comprising:  
2 (a) administering an agent of any one of claims 1-36 to a subject; and  
3 (b) detecting the presence of the agent;  
4 (c) producing an image representative of the enzymatically active prostate specific  
5 antigen, thereby imaging the presence of prostate cancer.
- 1 53. A method of treating a disease in a subject, comprising administering to a subject, an  
2 agent of any one of claims 1-36, wherein the agent comprises a radiolabel that localizes in  
3 the disease area and delivers an effective dose of radiation.
- 1 54. A method of *in vitro* imaging, comprising:  
2 (a) contacting a sample with an agent of any one of the claims 1-36;  
3 (b) allowing the agent to bind to a biological target; and  
4 (c) detecting a signal emitted from the agent to determine whether the agent has been  
5 activated by or bound to the biological target.
- 1 55. The method of claim 54, wherein the sample is a biological sample.

FIGURE 1




FIGURE 2A





FIGURE 2B





# INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2013/032200

A. CLASSIFICATION OF SUBJECT MATTER  
INV. A61K47/48 A61K49/00  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EP0-Internal, BIOSIS, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No. |
|-----------|---|-----------------------|
| X         | WO 2009/092062 A2 (VISEN MEDICAL INC [US];<br>RAJOPADHYE MILIND [US]; GROVES KEVIN [US];<br>PRE) 23 July 2009 (2009-07-23)<br>claims  | 1-55                  |
| X         | WO 2011/146143 A2 (OHMX CORP [US]; AHRENS<br>MICHAEL [US]; ANDERSON BYRON [US]; BERTIN<br>PAUL) 24 November 2011 (2011-11-24)<br>paragraph [0056] - paragraph [0064];<br>claims; figure 1 | 1-55                  |
| Y         | US 6 174 858 B1 (BRADY STEPHEN F [US] ET<br>AL) 16 January 2001 (2001-01-16)<br>claims  | 1-55                  |
|           | -----<br>-/--   |                       |



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

29 July 2013

Date of mailing of the international search report

06/08/2013

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Vogt, Titus

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2013/032200

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.       |
|-----------|--|-----------------------------|
| X         | US 2006/154324 A1 (WANG YUN-MING [TW] ET AL) 13 July 2006 (2006-07-13)<br><br>Scheme 3;<br>claims  | 1-4,6,7,<br>37-52,<br>54,55 |
| Y         | -----<br>DRAKE CHRISTOPHER R ET AL: "Activatable Optical Probes for the Detection of Enzymes", CURRENT ORGANIC SYNTHESIS, vol. 8, no. 4, August 2011 (2011-08), pages 498-520, XP009171540, ISSN: 1875-6271<br>figures 1, 2, 8 | 1-55                        |
| A         | -----<br>WO 2007/028163 A1 (VISEN MEDICAL INC [US]; RAJOPADHYE MILIND [US]; GROVES KEVIN [US]) 8 March 2007 (2007-03-08)<br>claims   | 1-55                        |
| A         | -----<br>WO 2007/028037 A1 (VISEN MEDICAL INC [US]; NARAYANAN NARASIMHACHARI [US]; GROVES KEVIN [U]) 8 March 2007 (2007-03-08)<br>claims<br><br>-----  | 1-55                        |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/032200

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| WO 2009092062 A2                          | 23-07-2009          | AU 2009205950 A1           | 23-07-2009          |
|   |                     | CA 2749108 A1              | 23-07-2009          |
|   |                     | EP 2244741 A2              | 03-11-2010          |
|   |                     | US 2009220430 A1           | 03-09-2009          |
|   |                     | WO 2009092062 A2           | 23-07-2009          |
| -----                                     |                     |                            |                     |
| WO 2011146143 A2                          | 24-11-2011          | CA 2798812 A1              | 24-11-2011          |
|   |                     | EP 2571997 A2              | 27-03-2013          |
|   |                     | US 2012034638 A1           | 09-02-2012          |
|   |                     | WO 2011146143 A2           | 24-11-2011          |
| -----                                     |                     |                            |                     |
| US 6174858 B1                             | 16-01-2001          | NONE                       |                     |
| -----                                     |                     |                            |                     |
| US 2006154324 A1                          | 13-07-2006          | JP 2006213705 A            | 17-08-2006          |
|   |                     | US 2006154324 A1           | 13-07-2006          |
| -----                                     |                     |                            |                     |
| WO 2007028163 A1                          | 08-03-2007          | EP 1937676 A1              | 02-07-2008          |
|   |                     | US 2008317676 A1           | 25-12-2008          |
|   |                     | WO 2007028163 A1           | 08-03-2007          |
| -----                                     |                     |                            |                     |
| WO 2007028037 A1                          | 08-03-2007          | AU 2006284565 A1           | 08-03-2007          |
|   |                     | CA 2621137 A1              | 08-03-2007          |
|   |                     | CN 101296927 A             | 29-10-2008          |
|   |                     | EP 1934211 A1              | 25-06-2008          |
|   |                     | JP 5106397 B2              | 26-12-2012          |
|   |                     | JP 2009507108 A            | 19-02-2009          |
|   |                     | JP 2012224646 A            | 15-11-2012          |
|   |                     | US 2009130024 A1           | 21-05-2009          |
|   |                     | WO 2007028037 A1           | 08-03-2007          |
| -----                                     |                     |                            |                     |